EP2666467A1 - Extract of aquatic animal cartilage - Google Patents
Extract of aquatic animal cartilage Download PDFInfo
- Publication number
- EP2666467A1 EP2666467A1 EP12737027.8A EP12737027A EP2666467A1 EP 2666467 A1 EP2666467 A1 EP 2666467A1 EP 12737027 A EP12737027 A EP 12737027A EP 2666467 A1 EP2666467 A1 EP 2666467A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cartilage
- amount
- proteoglycan
- fish cartilage
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 201
- 239000000284 extract Substances 0.000 title claims abstract description 151
- 241001465754 Metazoa Species 0.000 title abstract description 13
- 241000251468 Actinopterygii Species 0.000 claims abstract description 188
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 163
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 19
- 235000019688 fish Nutrition 0.000 claims description 186
- 239000000203 mixture Substances 0.000 claims description 80
- 210000002184 nasal cartilage Anatomy 0.000 claims description 69
- 241000972773 Aulopiformes Species 0.000 claims description 59
- 235000019515 salmon Nutrition 0.000 claims description 59
- 108010035532 Collagen Proteins 0.000 claims description 29
- 102000008186 Collagen Human genes 0.000 claims description 29
- 229920001436 collagen Polymers 0.000 claims description 29
- 206010061218 Inflammation Diseases 0.000 claims description 24
- 230000004054 inflammatory process Effects 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 19
- 239000002537 cosmetic Substances 0.000 claims description 14
- 241000277331 Salmonidae Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 29
- 230000008591 skin barrier function Effects 0.000 abstract description 18
- 210000001519 tissue Anatomy 0.000 abstract description 12
- 206010016807 Fluid retention Diseases 0.000 abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 108010067787 Proteoglycans Proteins 0.000 description 106
- 102000016611 Proteoglycans Human genes 0.000 description 106
- 238000000034 method Methods 0.000 description 88
- 239000000523 sample Substances 0.000 description 78
- 239000002253 acid Substances 0.000 description 61
- 238000000605 extraction Methods 0.000 description 61
- 239000000843 powder Substances 0.000 description 54
- 210000003491 skin Anatomy 0.000 description 48
- 102000004169 proteins and genes Human genes 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 46
- 229920002307 Dextran Polymers 0.000 description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 150000002632 lipids Chemical class 0.000 description 25
- 238000010438 heat treatment Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 230000036572 transepidermal water loss Effects 0.000 description 20
- 238000010298 pulverizing process Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 238000001641 gel filtration chromatography Methods 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 17
- 206010015150 Erythema Diseases 0.000 description 15
- 231100000321 erythema Toxicity 0.000 description 15
- 239000003550 marker Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 229920002683 Glycosaminoglycan Polymers 0.000 description 13
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229920002684 Sepharose Polymers 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 9
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000007710 freezing Methods 0.000 description 9
- 230000008014 freezing Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 8
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 210000003128 head Anatomy 0.000 description 8
- 238000003809 water extraction Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229940097043 glucuronic acid Drugs 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- -1 alkalis Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940059329 chondroitin sulfate Drugs 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000011800 void material Substances 0.000 description 5
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000007696 Kjeldahl method Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 238000000790 scattering method Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 244000303258 Annona diversifolia Species 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004380 ashing Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241000277334 Oncorhynchus Species 0.000 description 1
- 241000277326 Oncorhynchus gorbuscha Species 0.000 description 1
- 241000277329 Oncorhynchus keta Species 0.000 description 1
- 241000277269 Oncorhynchus masou Species 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 241000277277 Oncorhynchus nerka Species 0.000 description 1
- 241001280377 Oncorhynchus tshawytscha Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011899 heat drying method Methods 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 108700041430 link Proteins 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0066—Isolation or extraction of proteoglycans from organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Definitions
- the present invention relates to an extract of aquatic animal cartilage. More specifically, the present invention relates to an aquatic animal cartilage extract containing a proteoglycan having a high molecular weight.
- Proteoglycan is one of the major biological macromolecules for forming the substrate of the extracellular matrix of connective tissue, as are collagen and others.
- Proteoglycan was hitherto obtained by being extracted and isolated from mammal cartilage (in particular, bovine cartilage).
- bovine cartilage in particular, bovine cartilage
- BSE bovine spongiform encephalopathy
- proteoglycan As an alternative source for proteoglycan, aquatic animal tissue is attracting attention. Therefore, there have been attempts to extract proteoglycan from cartilage of aquatic animals, such as whales and sharks. However, due to catch restrictions placed on these aquatic animals, it has been difficult to produce a large amount of proteoglycan. Moreover, the extraction and isolation of proteoglycan is complicated, and some solvents, etc., used for extraction have high toxicity.
- Patent Document 1 discloses a method for producing a composition (nasal cartilage powder) containing proteoglycan from salmon nasal cartilage by using ethanol.
- Patent Document 1 JP2009-173702A
- An object of the present invention is to efficiently extract proteoglycan from aquatic animal tissues.
- the inventors of the present invention found a method of extracting proteoglycan from fish cartilage, which is aquatic animal cartilage, by using water. Moreover, the inventors further found that the fish cartilage water extract extracted from fish cartilage through this method contains proteoglycan of a molecular weight higher than that of the proteoglycan contained in the fish cartilage extracts obtained through hitherto known methods; further, they found that, the high molecular weight proteoglycan has a superior effect. After several attempts to further improve the extract based on these findings, the inventors completed the present invention.
- the present invention encompasses the inventions in the following items.
- the fish cartilage water extract of the present invention contains proteoglycan of a molecular weight higher than that of the proteoglycan contained in the fish cartilage extracts obtained through hitherto known methods. Further, the fish cartilage water extract of the present invention has a superior anti-aging effect (in particular, anti-inflammatory effect, skin barrier functionality improving effect, and skin water-retention ability improving effect). Moreover, the fish cartilage water extract of the present invention provides these effects not only through application to skin, but also through oral administration.
- Proteoglycan has a structure in which glycosaminoglycan (mucopolysaccharide) and protein are covalently bonded.
- Glycosaminoglycan is acidic saccharide consisting of a repeating disaccharide unit. Specifically, examples thereof include chondroitin sulfate, dermatan sulfate, and heparan sulfate.
- the repeating disaccharide units of the acidic saccharide components generally, one of the disaccharides is amino sugar, and the other is a uronic acid. Therefore, the detection of proteoglycan may be performed using a carbazole-sulfuric acid method, which is an ordinary method for detecting uronic acids.
- proteoglycan monomer a compound having a comb-like bond of glycosaminoglycan and protein.
- This protein in a proteoglycan monomer is called a core protein.
- the proteoglycan monomer is bonded to a hyaluronic acid via a link protein, thereby forming an aggregate.
- the aggregate is also called a proteoglycan aggregate.
- proteoglycan used in this specification encompasses a proteoglycan monomer and a proteoglycan aggregate.
- Hyaluronic acids are a kind of glycosaminoglycan.
- the fish cartilage water extract of the present invention contains a high molecular weight proteoglycan.
- the term "high molecular weight proteoglycan” used herein specifically refers to a proteoglycan having a molecular weight of not less than 1,800,000 (180 ⁇ 10 4 ), preferably a molecular weight of not less than 2,500,000 (250 ⁇ 10 4 ), not less than 3,500,000 (350 ⁇ 10 4 ), not less than 4,000,000 (400 ⁇ 10 4 ), not less than 5,000,000 (500 ⁇ 10 4 ), not less than 6,000,000 (600 ⁇ 10 4 ), not less than 7,000,000 (700 ⁇ 10 4 ), not less than 8,000,000 (800 ⁇ 10 4 ), not less than 9,000,000 (900 ⁇ 10 4 ), not less than 10,000,000 (1000 ⁇ 10 4 ), not less than 11,000,000 (1100 ⁇ 10 4 ), not less than 12,000,000 (1200 ⁇ 10 4 ), not less than 13,00,000 (1300 ⁇ 10 4 ), not less than 14,000,000 (1400 ⁇ 10
- a greater molecular weight is preferable.
- the fish cartilage water extract of the present invention is subjected to gel filtration chromatography under the following conditions, and the uronic acid amount (reflecting a proteoglycan amount) in each fraction is determined using a carbazole-sulfuric acid method.
- uronic acid amount chromatogram By creating a chromatogram based on the determined uronic acid amounts, it is possible to confirm the existence of proteoglycan having the above range of molecular weight.
- Such a chromatogram based on the uronic acid amount may be hereinafter referred to as "uronic acid amount chromatogram”.
- 280 nm protein amount chromatogram it is also possible to make a chromatogram based on the absorbencies by measuring absorbencies of the fractions at 280 nm, and then finding relative values of protein amounts based on the measurement results (i.e., the measurement values are assumed to be values that reflect the protein amounts).
- 280 nm protein amount chromatogram such a chromatogram may be referred to as "280 nm protein amount chromatogram”.
- Sepharose CL-2B packed column (1-cm dia. ⁇ 50 cm column packed with Sepharose CL-2B as a carrier.
- Sepharose CL-2B has a dextran fractionation range of 100 to 20,000 kDa and is available from GE Healthcare and other companies.
- 65099-79-8 is a 2% crosslinked agarose with a particle size of 60 to 200 ⁇ m (measured by the laser diffraction scattering method).
- Buffer 0.1 M phosphate buffer (pH of 7.1, containing 0.2 M NaCl)
- Amount of applied sample 4 mg of water extract of fish cartilage (on a dry mass basis) (dissolved in 1 mL of buffer for use)
- Flow rate 0.15 mL/min
- Amount of fraction 1 mL/tube
- Molecular weight analytical curve The various dextran molecular weight markers described below are subjected to gel filtration chromatography under the same conditions as described above, absorbency (which reflects the amount of dextran) of each fraction is measured by the phenol-sulfuric acid method, which is a well-known method for detecting saccharide, a fraction at which each marker is eluted is determined, and an analytical curve reflecting the molecular weight of the component contained in each fraction in the gel filtration chromatography under the
- fraction at which each marker is eluted refers to a fraction at which each marker is eluted most, i.e., a fraction corresponding to a peak maximum in a chromatogram reflecting the amount of dextran when each dextran molecular weight marker is subjected to gel filtration.
- Dextran from Leuconostoc mesenteroides (mol wt 5,000,000 - 40,000,000)(Sigma) ...
- 20,000 kDa Dextran Standard 1,400,000 (Sigma) ... 1400 kDa Dextran Standard 670,000 (Sigma) ... 670 kDa Dextran Standard 410,000 (Sigma) ... 410 kDa Dextran Standard 270,000 (Sigma) ... 270 kDa
- the dextran from Leuconostoc mesenteroides is used as a marker after pretreatment is carried out to remove low molecular weight dextran contained in the marker.
- the pretreatment is performed by eluting dextran from Leuconostoc mesenteroides under the conditions described above in "Gel Filtration Chromatography Conditions" and collecting and freeze-drying fractions having a molecular weight of not less than 20,000 kDa. More specifically, fractions that correspond to a peak that first appears in a chromatogram reflecting the amount of dextran are collected and freeze-dried.
- the chromatogram is prepared by measuring absorbency of each fraction by the phenol-sulfuric acid method.
- dextran having a molecular weight of not less than 20,000 kDa is obtained by collecting and freeze-drying such fractions.
- This freeze-dried product is actually used as a marker (for measuring the void volume of the column).
- Measurement of absorbency to obtain a chromatogram reflecting the amount of dextran is performed according to the method (the phenol-sulfuric acid method) described in Hodge, J. E., and Hookter, B. T., Method in Carbohydrate Chemistry, 1, 338 (1962 ). More specifically, the measurement is carried out as follows.
- the carbazole-sulfuric acid method refers to a well-known method performed by adding a carbazole solution, which is a color component of uronic acid (glucuronic acid (Glc A), iduronic acid, etc.), to a measurement specimen, and measuring the absorbency by using a spectrophotometer, thereby finding uronic acid amount based on the absorbency.
- An analytical curve is plotted using the glucuronic acid standard solution having a specific concentration, thereby finding the glucuronic acid content in the specimen. More specifically, the carbazole-sulfuric acid method is performed as follows.
- a reagent obtained by dissolving 0.95 g of sodium borate decahydrate in 100 ml of a concentrated sulfuric acid is placed in a test tube and ice-cooled.
- 0.5 ml of a test object (preferably containing 2 to 20 ⁇ g of uronic acid) is gently layered thereon. The mixture is stirred well while being ice-cooled, thereby keeping it at room temperature or below.
- the test tube is covered with a glass ball, the test tube is heated in a boiling water bath for 10 minutes, followed by water cooling to decrease the temperature to room temperature.
- the uronic acid amount of a proteoglycan having a molecular weight of not less than 2,500,000 (250 ⁇ 10 4 ) is preferably at least 10 mass% based on the total uronic acid amount of the fish cartilage water extract of the present invention.
- the uronic acid amount is more preferably not less than 15 mass%, not less than 20 mass%, not less than 25 mass%, not less than 30 mass%, not less than 35 mass%, not less than 40 mass%, not less than 45 mass%, not less than 50 mass%, not less than 55 mass%, or not less than 60 mass%. The greater the mass%, the more desirable.
- a uronic acid amount of proteoglycan having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ) is preferably at least 7 mass% based on the total uronic acid amount of the fish cartilage water extract of the present invention.
- the uronic acid amount of proteoglycan having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ) is more preferably not less than 10 mass%, not less than 13 mass%, not less than 16 mass%, not less than 20 mass%, not less than 24 mass%, not less than 27 mass%, not less than 30 mass%, not less than 34 mass%, not less than 37 mass%, or not less than 40 mass%. The greater the mass%, the more desirable.
- the proportion of the uronic acid amount of a proteoglycan having a molecular weight of not less than a specific value (which is expressed as X hereinbelow) based on the total uronic acid amount in the extract can be found from a peak area in the aforementioned uronic acid amount chromatogram. More specifically, the proportion can be found by calculating a proportion of the area of a uronic acid having a molecular weight of not less than X based on the entire peak area of the uronic acid amount chromatogram.
- a vertical line is drawn so that the vertical line passes through the fraction containing the proteoglycan having a molecular weight X; and then, from the two peak areas divided by the vertical line, a peak area containing proteoglycan of a greater molecular weight is determined and the proportion of the peak area based on the total peak area is found.
- the uronic acid amount (measured by the carbazole-sulfuric acid method) contained in the fish cartilage water extract of the present invention is, on a dry mass basis, preferably not less than 5 mass%, more preferably not less than 10 mass%, even more preferably not less than 15 mass%, still more preferably not less than 20 mass%, particularly preferably not less than 25 mass%.
- the term "GlcA” may be used as an abbreviation for glucuronic acid (e.g., "GlcA( ⁇ g)"
- the fish cartilage water extract of the present invention preferably contains proteoglycan having a molecular weight of not less than 1,800,000 (180 ⁇ 10 4 ) in an amount of, on a dry mass basis, not less than 30 mass%, more preferably not less than 35 mass% of the extract.
- the fish cartilage water extract of the present invention preferably contains proteoglycan having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ) in an amount of, on a dry mass basis, not less than 5 mass%, not less than 10 mass%, not less than 15 mass%, not less than 20 mass%, not less than 25 mass%, not less than 30 mass%, or not less than 35 mass% of the extract. A greater proportion is more desirable.
- the fish cartilage water extract of the present invention contains only a small amount of lipid.
- the mass ratio of lipid to proteoglycan (lipid amount/proteoglycan amount) in the fish cartilage water extract of the present invention is preferably smaller than the mass ratio of lipid to proteoglycan (lipid amount/proteoglycan amount) in fish cartilage used as the raw material of the extract.
- the lipid content in the fish cartilage water extract of the present invention is, on a dry mass basis, preferably not more than 5 mass%, more preferably not more than 4 mass%, even more preferably not more than 3 mass%, still more preferably not more than 2 mass%, particularly preferably not more than 1 mass%.
- such a fish cartilage water extract can be obtained by using defatted fish cartilage (fish cartilage from which lipid is removed). Further, the fish cartilage water extract may also be obtained by defatting the resulting extract using a known defatting method.
- most of the protein contained in fish cartilage extract of the present invention is preferably collagen (preferably type II collagen). More specifically, preferably not less than 80 mass%, more preferably not less than 85 mass% of the protein is collagen.
- the amount of collagen in the fish cartilage extract of the present invention is, on a dry mass basis, preferably not less than 30 mass%, more preferably 30 to 60 mass%.
- the ash content in the fish cartilage extract of the present invention is, on a dry mass basis, preferably not more than 15 mass%, more preferably 5 to 15 mass%, even more preferably 5 to 10 mass%.
- the protein amount above is found by measuring the nitrogen amount in the sample using the Kjeldahl method, and subtracting the glycosaminoglycan-derived nitrogen amount from the above nitrogen amount; i.e., the protein amount is the amount excluding the amount of proteoglycan-derived protein. Further, the ash content is found by the direct ashing method. Further, the collagen amount is found by measuring the hydroxy proline amount in the sample using the automatic amino acid analysis (HPLC method), and calculating the collagen amount assuming that the collagen contains 6.7% hydroxy proline.
- HPLC method automatic amino acid analysis
- the fish cartilage water extract of the present invention is extracted from fish cartilage, preferably from Oncorhynchus ( Salmonidae ) cartilage, including trout (humpback salmon, cherry salmon, satsukimasu salmon, etc.), salmon (chum salmon, sockeye salmon, silver salmon, chinook salmon, steelhead, etc.), shark, and cod. Salmon and trout are particularly preferable.
- the cartilage to be used is not particularly limited; however, head cartilage, in particular, nasal cartilage, is preferable.
- fish (in particular, salmon and trout) heads are usually discarded when fish is processed into food products, the cost of fish heads is low, and a large amount of fish heads can be stably supplied.
- the extraction is performed using water. It is possible to subject fish cartilage obtained from a biological sample to extraction as it is; however, the fish cartilage may also be subjected to extraction after being pulverized (more specifically, pulverized into small pieces or powder). Further, as described below, it is also possible to subject fish cartilage to a defatting treatment using ethanol or the like before the extraction. As such, proteoglycan (including a high molecular weight proteoglycan) can be extracted using water. More specifically, the fish cartilage water extract of the present invention is preferably extracted from fish cartilage by using water. It is also possible to perform water extraction while heating water, or by using hot or boiling water. With this method, a fish cartilage water extract with a greater effect can be efficiently obtained.
- the small pieces of fish cartilage are obtained by pulverizing fish cartilage into small pieces.
- the pulverization may be performed using a known method.
- the pulverization of fish cartilage (preferably frozen fish cartilage) into small pieces may be performed using known devices such as a blender or a mill.
- the pulverization is preferably performed at a low temperature.
- the pulverization is preferably performed at a temperature at which the pulverized fish cartilage can be kept frozen. More specifically, the pulverization is preferably performed at a temperature of 0°C or less.
- small frozen pieces of fish cartilage can be obtained by (i) freezing fish cartilage and then pulverizing it into small pieces, or by (ii) pulverizing fish cartilage into small pieces and then freezing it.
- the small frozen pieces of fish cartilage obtained by method (i) are more preferable.
- the freezing method is not particularly limited, and any known freezing method can be used. For example, a method of storing fish cartilage in a freezer at about -20 to -80°C for about 24 to 72 hours can be used.
- the small pieces of fish cartilage or small frozen pieces of fish cartilage are preferably about 0.001 to 0.5 g, more preferably about 0.005 to 0.3 g, even more preferably about 0.01 to 0.1 g per piece.
- the pulverization of fish cartilage into small pieces is preferably performed in a manner enabling production of such small pieces. (The conditions for obtaining such small pieces can be easily obtained by appropriately selecting and adjusting the device to be used.)
- the fish cartilage powder is obtained by pulverizing fish cartilage into powder (powdered fish cartilage).
- the pulverization may be performed using a known method.
- the pulverization of fish cartilage (preferably frozen fish cartilage) into powder may be performed using known devices such as a blender or a mill.
- the pulverization is preferably performed at a low temperature (e.g., not more than 0°C).
- the frozen fish cartilage powder can be obtained by (i') freezing fish cartilage and then pulverizing it into powder, or by (ii') pulverizing fish cartilage into powder and then freezing it.
- the frozen fish cartilage powder obtained by method (i') is more preferable.
- the freezing method is not particularly limited, and any known freezing method can be used. For example, a method of storing fish cartilage in a freezer at about -20 to -80°C for about 24 to 72 hours can be used.
- powder refers to a piece smaller than what is referred to by the term “small pieces”; however, these terms are not necessarily distinguished clearly.
- small pieces relatively large pieces are referred to as “small pieces”, and relatively small pieces are referred to as “powder”. Therefore, although it is not particularly limited, powder preferably contains particles having a particle size of about 10 to 1000 ⁇ m, preferably about 50 to 500 ⁇ m, more preferably about 100 to 200 ⁇ m (measured by a laser diffraction and scattering method). However, the particle size is not particularly limited to these ranges.
- the powder preferably contains particles having the above particle size in a large proportion (e.g., not less than 50 mass%, preferably not less than 70 mass%).
- Small defatted pieces of fish cartilage or fish cartilage powder may also be used.
- small defatted fish cartilage pieces or defatted fish cartilage powder may also be used.
- defatted fish cartilage a highly purified fish cartilage water extract that incorporates less lipid can be obtained.
- the small defatted fish cartilage pieces or defatted fish cartilage powder can be obtained by ( ⁇ ) pulverizing defatted fish cartilage into small pieces or powder, or by ( ⁇ ) pulverizing the fish cartilage into small pieces or powder and then defatting the small pieces or powder.
- the defatting may be performed by a known method.
- fish cartilage defatting step ( ⁇ ) above may be performed by a method of running fish cartilage under water (e.g., tap water) for about 1 to 24 hours.
- Preparation of fish cartilage can be performed using a known method, including a method of immersing fish tissues (preferably a fish head) in water for about 1 to 24 hours to make the tissue swell, and removing tissues other than cartilage (preferably nasal cartilage), and a method of thawing a frozen salmon head, then immediately separating the nasal cartilage and running the nasal cartilage under water for about 1 to 24 hours, thereby washing and defatting the cartilage.
- cartilage has residual flesh, it is preferable to remove the flesh with tweezers or the like. At this point, since the fish cartilage has not been pulverized into small pieces or powder, it is likely that little proteoglycan will be extracted even after running the cartilage under water. Further, as in step ( ⁇ ) below, lipid can be removed using an organic solvent.
- the method for defatting the small fish cartilage pieces or fish cartilage powder in step ( ⁇ ) above may be performed by extracting and removing lipid using an organic solvent.
- organic solvents include ethanol, hexane, acetone, and the like.
- step ( ⁇ ) a method disclosed in Patent Document 1 ( JP2009-173702A ) can be preferably used.
- defatted fish cartilage powder, which is obtained by a method including the following steps A to E can be preferably used for the present invention. (Patent Document 1 also discloses more detailed conditions.)
- small frozen and defatted fish cartilage pieces or fish cartilage powder small frozen and defatted fish cartilage pieces or frozen and defatted fish cartilage powder. These can be obtained, for example, by freezing defatted fish cartilage and pulverizing the frozen fish cartilage into small pieces or powder.
- the fish cartilage preferably small fish cartilage pieces, or fish cartilage powder (which hereinafter may be referred to collectively as “fine fish cartilage”)
- fine fish cartilage water used for water extraction
- water used for water extraction include Milli-Q water, distilled water, deionized water, purified water, and tap water.
- the pH of the extraction water is generally about 5.5 to 8.0, preferably about 6.0 to 7.5, more preferably about 6.5 to 7.5. It is not preferable to dissolve substances that greatly change the pH, such as acids, alkalis, bases, and the like.
- an acid compound such as organic acid or inorganic acid, or an alkali compound such as sodium hydroxide
- a high molecular weight proteoglycan in particular, a high molecular weight proteoglycan having a molecular weight of 10,000,000 (1000 ⁇ 10 4 )
- acid compounds or alkali compounds are not preferable to add.
- a restrictive interpretation is not desired, this is presumably because acid compounds and alkali compounds cause degradation of proteoglycan aggregates during extraction.
- the water extract can be obtained, for example, by immersing fish cartilage in water for an appropriate amount of time (e.g., not less than 30 minutes, preferably about 30 minutes to 24 hours, more preferably about 1 to 12 hours, even more preferably about 2 to 6 hours, still more preferably about 3 to 4 hours).
- the amount of water is not particularly limited; for example, the water amount is a sufficient amount for completely immersing all the small fish cartilage pieces or fish cartilage powder subjected to extraction in water.
- the fish cartilage pieces or powder may be allowed to stand still; more preferably it may be stirred.
- the water temperature during the extraction is not particularly limited; however, the temperature is preferably not less than 50°C, more preferably not less than 70°C.
- the water may be heated during the extraction or before the extraction.
- the heating temperature i.e., the temperature of the water used
- the heating may be performed under an increased pressure. Since heating may cause degradation of high molecular weight proteoglycan, the heated extraction water may be replaced during the extraction.
- the interval between replacements of extraction water is, for example, every 15 minutes to 4 hours, preferably every 30 minutes to 2 hours, or about 1 hour.
- a method of adding water (preferably heated water) to fish cartilage in a sufficient amount for completely immersing the total amount of fish cartilage, and allowing it to stand or stirring it for 3 to 4 hours while heating may be used.
- Another preferable method is repeatedly performing a process of adding water (preferably heated water) to fish cartilage in a sufficient amount for completely immersing the total amount of fish cartilage, allowing it to stand for an hour while heating, and collecting the resulting water. (In this case, the water extraction takes 4 hours in total.)
- the liquid portion is collected to obtain a fish cartilage water extract.
- the collection of the liquid portion is performed by removing the supernatant through, for example, a centrifugation treatment (e.g., centrifugation at 5000 rpm, 4°C, for 20 minutes) or a continuous centrifugation treatment.
- the liquid (supernatant) may be used, as it is, as the fish cartilage water extract of the present invention, or it may further be purified by a known method (e.g., defatting). It is also possible to concentrate the liquid by distillation under reduced pressure or the like. It is also possible to dry or powderize the liquid according to the freeze-drying method or the spray drying method.
- the fish cartilage water extract of the present invention thus obtained may be used as, for example, materials for food, cosmetics, oral compositions, medicinal products, and the like.
- the fish cartilage water extract of the present invention may be suitably used for, in particular, skin anti-aging.
- Skin is constantly exposed to various kinds of damage.
- the epidermis barrier functionality decreases due to external factors (e.g., light irradiation such as ultraviolet) or internal factors (e.g., aging).
- Such damage causes an increase in transepidermal water loss (TEWL), thereby causing dry skin, rough skin or the like.
- TEWL transepidermal water loss
- a decrease in the ability to produce collagen, a decrease in skin elasticity, or thickening of the dermis may occur in the dermal layer, thereby furthering hardening of the skin. This may result in wrinkles or the like.
- the fish cartilage water extract of the present invention exhibits various effects (anti-inflammatory effect, skin barrier functionality improving effect, skin water-retention ability improving effect, and cell proliferation promoting effect) to inhibit or alleviate such skin symptoms.
- the fish cartilage water extract of the present invention is suitable to prevent or alleviate these skin symptoms caused by light irradiation (exposure) (in particular, ultraviolet irradiation).
- the degree of the cell proliferation promoting effect varies depending on the temperature during water extraction. This is presumably because the temperature change during water extraction changes the composition of the fish cartilage water extract.
- the usage of the fish cartilage water extract of the present invention is not limited; however, since the fish cartilage water extract of the present invention provides the aforementioned effects through embrocation or oral administration, the fish cartilage water extract of the present invention is suitable for compositions for external use or oral compositions. More specifically, the fish cartilage water extract of the present invention is preferably used as a composition for external use or an oral composition. These compositions may be used as a medicinal composition, a quasi-drug composition, an oral composition, a cosmetic composition, a food composition, and the like. They may be produced by a standard method using the fish cartilage water extract of the present invention. They are particularly useful for products in the oral-care industry, skin-care industry, hair-care industry, and health-care industry.
- the oral compositions containing the fish cartilage water extract of the present invention (which may be hereinafter referred to as oral compositions of the present invention) used in the oral-care industry may be the fish cartilage water extract of the present invention itself, or a composition produced by appropriately combining the fish cartilage water extract of the present invention with other components (e.g., abrasives, binders, surfactants, excipients, wetting agents, pH adjusters, thickeners, sweetening agents, preservatives, medicinal components, coloring agents, flavoring agents, and the like) generally used for oral compositions.
- the oral composition products include paste agents, ointments, gels, embrocations, sprays, supplements, liquids, mouthwashes, pastes, chewing gum, troches, and tablets, which may be manufactured by standard methods.
- Such oral compositions of the present invention can be preferably used for alleviation of inflammation in oral tissues, anti-aging in oral tissues, and prevention or alleviation of dryness of the oral tissues. More specifically, the oral compositions of the present invention encompass an inflammation alleviation oral composition, an anti-aging oral composition, a tissue-repairing oral composition, and an oral dryness prevention/alleviation oral composition.
- the cosmetic composition (hereinafter may be referred to as "cosmetic composition of the present invention") containing the fish cartilage water extract of the present invention used as hair-care products or skin-care products may be the fish cartilage water extract of the present invention itself, or a composition produced by appropriately combining the fish cartilage water extract of the present invention with cosmetically acceptable surfactants, wetting agents, polymeric agents, powder, esters, alcohols, plant or animal oils, medicinal agents, preservatives, coloring agents, flavoring agents, or other cosmetically acceptable components or materials using a standard method.
- the cosmetic compositions produced by incorporating the fish cartilage water extract of the present invention include hair restorers, hair tonics, emulsions, lotions, creams, serums, face packs, face masks, and sunscreens.
- Such a cosmetic composition of the present invention may be preferably used for alleviation of inflammation, anti-aging, or moisture retention.
- preferable usages include compositions for hair restoration, scalp care, sun protection, sunburn care, moisturizing and anti-aging of the skin (e.g., prevention or alleviation of dry skin, rough skin, facial wrinkles, or sagging skin).
- the food and beverage compositions (beverages and food) containing the fish cartilage water extract of the present invention (which may be hereinafter referred to as food and beverage compositions of the present invention) used in the health-care industry may be the fish cartilage water extract of the present invention itself, or a composition produced by appropriately combining the fish cartilage water extract of the present invention with bases, carriers or additives that are acceptable in terms of food hygiene, or other components or materials that are used for food and beverages.
- Examples of these include processed food and beverages containing the fish cartilage water extract of the present invention with claimed effects of moisturizing and anti-aging of the skin (e.g., prevention or alleviation of dry skin, rough skin, facial wrinkles, or sagging skin), dietary supplements, food for special purposes (food for patients, food for specific health uses, food for patients deglutition disorder, etc.) and beauty food.
- the present invention also includes moisturizers and skin anti-aging agents formed of the aforementioned food and beverage compositions of the present invention.
- the moisturizers and skin anti-aging agents may be supplied in the forms of drinks, pills, tablets, capsules, granules, jelly, troches, pastes, viscous liquids, powder, block bars, or the like for cosmetic or skin anti-aging purposes (e.g., prevention or alleviation of dry skin, rough skin, facial wrinkles, or sagging skin).
- the amount of the fish cartilage water extract contained in the compositions for external use or oral composition (in particular, oral compositions, cosmetic compositions, or food or beverage compositions of the present invention) containing the fish cartilage water extract of the present invention is, for example, but not limited to, generally 0.0001 to 100 mass%, preferably 0.001 to 50 mass%, more preferably 0.005 to 30 mass%, even more preferably 0.01 to 20 mass%, based on the entire composition.
- the amount of uronic acid derived from proteoglycan having a molecular weight of not less than 2,500,000 (250 ⁇ 10 4 ) in the composition is, for example, about 0.00001 to 10 mass%, preferably about 0.0001 to 5 mass%, more preferably about 0.0005 to 1 mass%, based on the entire composition.
- the present invention also encompasses methods for obtaining the various effects disclosed in this specification, including a method for alleviating inflammation on the skin or in the oral cavity, a method for enhancing or improving barrier functionality, and a method for promoting cell (in particular, fibroblast) proliferation, by applying the fish cartilage water extract of the present invention to skin or the oral cavity.
- These methods may be performed using the fish cartilage water extract of the present invention as it is, more preferably, using the above compositions for external use, or oral compositions or cosmetic compositions of the present invention.
- the target subject of the method is not particularly limited; however, the method is preferably used for subjects having inflammation or subjects having decreased skin barrier functionality due to aging or sunburn. The method may also be used not only for treatment purposes but also for cosmetic purposes.
- the method is particularly suitable for cosmetic purposes for enhancing barrier functions.
- the target subjects are preferably mammals, including humans. More specifically, non-human mammals can also be target subjects. Examples of non-human mammals include pet animals or livestock, including dogs, cats, apes, mice, rats, hamsters, rabbits, cows, horses, swine, sheep, goats, Ilamas, and camels.
- the application amount is also not limited, and a suitable effective amount can be determined.
- the dosage of the fish cartilage water extract by adjusting the amount of proteoglycan, for example, so that the amount of the uronic acid derived from a high molecular weight proteoglycan having a molecular weight of not less than 2,500,000 (250 ⁇ 10 4 ) (more preferably, not less than 5,000,000 (500 ⁇ 10 4 )) is preferably about 0.1 to 500 mg, more preferably about 0.5 to 250 mg, even more preferably about 1 to 100 mg, per adult/day.
- the present invention also encompasses methods for obtaining the various effects disclosed in this specification, including a method for alleviating inflammation on the skin or in the oral cavity, a method for enhancing or improving skin barrier functionality, a method for inhibiting thickened skin and a method for improving skin water retention ability, through oral administration of the fish cartilage water extract of the present invention.
- These methods may be performed using the fish cartilage water extract of the present invention as it is, more preferably, using the oral compositions described above, or food and beverage compositions of the present invention.
- medicinal compositions containing the fish cartilage water extract of the present invention are also preferably used.
- the target subject of the method is not particularly limited; however, the method is preferably used for subjects who developed inflammation, or subjects with decreased skin barrier functionality or skin water retention ability due to aging or sunburn.
- the method may also be used for cosmetic purposes.
- the target subjects are preferably mammals including humans. More specifically, non-human mammals can also be target subjects. Examples of non-human mammals include pet animals or livestock, including dogs, cats, apes, mice, rats, hamsters, rabbits, cows, horses, swine, sheep, goats, Ilamas, and camels.
- the application amount is also not limited, and a suitable effective amount can be determined.
- the dosage of the fish cartilage water extract by adjusting the amount of proteoglycan, for example, so that the amount of the uronic acid derived from the high molecular weight proteoglycan having a molecular weight of not less than 2,500,000 (250 ⁇ 10 4 ) (more preferably, not less than 5,000,000 (500 ⁇ 10 4 )) is about 0.2 to 1000 mg, more preferably about 1 to 800 mg, even more preferably about 2 to 500 mg, per adult/day.
- Salmon nasal cartilage used for the analysis was obtained by separating nasal cartilage immediately after thawing a frozen salmon head, washing and defatting the nasal cartilage by running it under water for 6 hours, removing pieces of flesh and the like with tweezers, and washing the nasal cartilage with water by hand.
- Salmon nasal cartilage was stored and frozen in a freezer, and the frozen nasal cartilage was used as a frozen salmon nasal cartilage block.
- the frozen salmon nasal cartilage block had a size of about 2.5 ⁇ 1.5 cm to about 4.5 ⁇ 2 cm and a weight of about 1.71 g to about 6.91 g. (The average weight of 7 blocks was 3.701 g.), although the size and weight depend on the size of the salmon head used.
- Fig. 1a shows a photo of a frozen salmon nasal cartilage block.
- Frozen salmon nasal cartilage blocks from item (1) above were placed in a blender and crushed for 10 seconds to prepare small pieces of frozen salmon nasal cartilage.
- Fig. 1b shows a photo of small pieces of frozen salmon nasal cartilage. Twenty pieces were randomly collected, and the size and the mass of each piece were analyzed. Each piece had a size of about 0.2 cm to about 0.7 cm and a mass of about 0.0116 to about 0.0890 g. (The average weight of 20 pieces was 0.033 g.) From 100 g of the frozen salmon nasal cartilage blocks, 95.6 g of small pieces of frozen salmon nasal cartilage was obtained.
- Defatted salmon nasal cartilage powder was prepared using frozen salmon nasal cartilage from item (1) above by the method disclosed in Example 1 of Patent Document 1 ( JP2009-173702A ). From 100 g of the frozen salmon nasal cartilage blocks, 5.83 g of defatted salmon nasal cartilage powder was obtained. Fig. 1c shows a photo of defatted salmon nasal cartilage powder.
- Example 1 of Patent Document 1 Frozen salmon nasal cartilage (100 g) was crushed, and an equal volume of tap water at 15°C was added to the crushed salmon nasal cartilage. The mixture was gently stirred to mix it thoroughly, and the mixture, which was maintained at about 5°C, was immediately centrifuged with a centrifugal separator at 9,000 rpm at 4°C for 30 minutes to separate lipid and other components including proteoglycan. Three layers were obtained after the centrifugation. The lipid layer in the upper layer and the aqueous layer in the middle layer were removed, and the precipitate was collected. The precipitate was freeze-dried and then pulverized with a centrifugal mill to prepare a water-defatted fine powder.
- Extraction of proteoglycan was attempted by adding water to small pieces of frozen salmon nasal cartilage prepared as described above in item (2), and allowing the mixture to stand, or heating the mixture at 100°C. More specifically, analysis was carried out as follows. Four samples were prepared. Each sample was prepared by adding 60 mL of distilled water to about 12 g of the small pieces of frozen salmon nasal cartilage. These four samples were heated at 100°C for 1 hour, 2 hours, 3 hours, and 4 hours, respectively, and each sample was centrifuged with a centrifugal separator at 5,000 rpm at 4°C for 20 minutes to remove insoluble matter (residue) and collect the supernatant.
- the amount of uronic acid in the supernatant was measured by the carbazole-sulfuric acid method.
- the amount of uronic acid reflects the amount of proteoglycan.
- the amount of uronic acid may be represented using the term "GlcA," an abbreviation of glucuronic acid, which is a uronic acid.
- the amount of protein in the collected supernatant was measured by the Bradford method. The results are shown in Table 1.
- Fig. 2 is a graphical representation of Table 1.
- Proteoglycan was also extracted from the frozen salmon nasal cartilage blocks from item (1) and from the defatted salmon nasal cartilage powder from item (3) in the same manner as for the small pieces of frozen salmon nasal cartilage from item (2) above (except that the heating time and the heating temperature were changed), and the extraction amounts thereof were compared.
- the results are shown in Table 2.
- Table 2 the amount of extracted uronic acid and the amount of extracted protein are represented in terms of amounts per 100 g of the frozen salmon nasal cartilage blocks.
- the amount of protein was measured by the Bradford method.
- Fig. 3 is a graphical representation of Table 2. The descriptions of the samples (1 to 9) shown in Fig. 3 correspond to the descriptions of 1 to 9 of the Sample No. column in Table 2.
- the water extract of fish cartilage may be hereinafter referred to as Sample No. 10.
- Sample No. 10 was separated into fractions by gel filtration chromatography under the conditions described below.
- the amount of uronic acid contained in each fraction was quantified by the carbazole-sulfuric acid method.
- absorbency at 280 nm of each fraction was measured, and the absorbency was defined as a value reflecting the amount of protein contained therein.
- a uronic acid amount chromatogram and a 280-nm protein amount chromatogram were drawn.
- Fig. 4a shows a superimposition of the uronic acid amount chromatogram and the 280-nm protein amount chromatogram.
- Fig. 4b shows the uronic acid amount chromatogram together with the position of each fraction at which each molecular weight marker was eluted. Since the amount of each fraction in the gel filtration chromatography was 1 mL/tube as described below, the horizontal axis, "Elution Volume (mL)", in Fig. 4 also reflects the fraction No.
- Sepharose CL-2B packed column (1-cm dia. ⁇ 50 cm column packed with Sepharose CL-2B as a carrier.
- Sepharose CL-2B has a dextran fractionation range of 100 to 20,000 kDa and is available from GE Healthcare and other companies.
- Sepharose CL-2B, CAS registry No. 65099-79-8 is a 2% crosslinked agarose with a particle size of 60 to 200 ⁇ m (measured by the laser diffraction scattering method).)
- Buffer 0.1 M phosphate buffer (pH of 7.1, containing 0.2 M NaCl)
- Amount of applied sample 4 mg of Sample No.
- Dextran from Leuconostoc mesenteroides (mol wt 5,000,000 - 40,000,000)(Sigma) ...
- 20,000 kDa Dextran Standard 1,400,000 (Sigma) ... 1400 kDa Dextran Standard 670,000 (Sigma) ... 670 kDa Dextran Standard 410,000 (Sigma) ... 410 kDa Dextran Standard 270,000 (Sigma) ... 270 kDa
- the dextran from Leuconostoc mesenteroides was used after pretreatment was carried out to remove low molecular weight dextran contained in the marker.
- the pretreatment was performed by eluting dextran from Leuconostoc mesenteroides under the conditions described above in "Gel Filtration Chromatography Conditions" (the applied amount was the amount for marker) and collecting and freeze-drying fractions having a molecular weight of not less than 20,000 kDa. More specifically, fractions that corresponded to a peak that appeared first in a chromatogram reflecting the amount of dextran were collected and freeze-dried. The chromatogram was prepared by measuring the absorbency of each fraction by the phenol-sulfuric acid method.
- Sample No. 10 was found to contain proteoglycan having a molecular weight of not less than 2,000,000 (200 ⁇ 10 4 ) (further, a molecular weight of not less than 2,500,000 (250 ⁇ 10 4 )).
- the ratio of the component having not less than (or not greater than) a specific molecular weight contained in the water extract of fish cartilage can be determined by drawing a vertical line from an elution volume point corresponding to the specific molecular weight in the uronic acid amount chromatogram and calculating the ratio of the two areas of the chromatogram divided by the vertical line.
- Sample No. 10 was analyzed in more detail. More specifically, the analysis was carried out as follows. Sample No. 10 was subjected to ion-exchange chromatography under the conditions described below to fractionate proteoglycan. More specifically, 16 mL eluted fractions were collected to quantify the amount of uronic acid by the carbazole-sulfuric acid method.
- uronic acid amount chromatogram was shown in Fig. 5 .
- Fractions containing uronic acid shown in Fig. 6 as a left-right arrow) were collected, dialyzed, and then freeze-dried to obtain powder.
- the powder was used as a "proteoglycan fraction" for the following analysis.
- the proteoglycan fraction obtained as described above was subjected to gel filtration chromatography under the following conditions and fractionated.
- the amount of uronic acid contained in each fraction was quantified by the carbazole-sulfuric acid method.
- absorbency at 280 nm of each fraction was measured and the absorbency was defined as a value reflecting the amount of protein contained therein. Based on these results, a uronic acid amount chromatogram and a 280-nm protein amount chromatogram were drawn.
- the dextran from Leuconostoc mesenteroides was used after pretreatment was carried out to remove low molecular weight dextran contained in the marker.
- the pretreatment was performed by eluting dextran from Leuconostoc mesenteroides under the conditions described above in "Gel Filtration Chromatography Conditions" (the applied amount was the amount in the marker treatment), and collecting and freeze-drying fractions having a molecular weight of not less than 20,000 kDa. More specifically, fractions that corresponded to a peak that first appeared in a chromatogram reflecting the amount of dextran were collected and freeze-dried.
- dextran having a molecular weight of not less than 20,000 kDa was obtained by collecting and freeze-drying such fractions.
- This freeze-dried product was actually used as a marker (for measuring the void volume of the column).
- Measurement of absorbency to obtain a chromatogram reflecting the amount of dextran was performed in the same manner as described above.
- Fractions containing uronic acid were divided into three groups: a group having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ), a group having a molecular weight of not less than 400,000 (40 ⁇ 10 4 ) to less than 5,000,000 (500 ⁇ 10 4 ), and a group having a molecular weight of less than 400,000 (40 ⁇ 10 4 ).
- the fractions were collected, dialyzed, and then freeze-dried to obtain three types of water extracts (powder) of fish cartilage having different molecular weights.
- PG-1 extract containing proteoglycan having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 )
- PG-2 extract containing proteoglycan having a molecular weight of not less than 400,000 (40 ⁇ 10 4 ) to less than 5,000,000 (500 ⁇ 10 4 )
- PG-3 extract containing proteoglycan having a molecular weight of less than 400,000 (40 ⁇ 10 4 )
- a water extract of fish cartilage was actually given to mammals, and the effects of the extract were analyzed.
- Hairless mice Hr-/Kud, male (Kyudo Co., Ltd.) were used for the experiment.
- mice were placed in three feeding cages as shown in Table 3 to be divided into groups (Groups 1 to 3)(six mice in one group).
- the subjects were marked on their tail portion to be individually identified. They continued to be preliminarily fed until the start of analysis.
- the average body weight during the experiment was 37 g.
- Sample No. 10 was used as the water extract of fish cartilage for Group 3 in Table 3, which is an evaluation material.
- Sample No. 10 was dissolved in water to 0.35 mg/mL to prepare an administration sample.
- UVB irradiation started 3 weeks after oral administration began.
- the mice were placed in a cage for UVB irradiation.
- the cage was placed into a UVB irradiation device to carry out UVB irradiation 6 times per week (once a day for 6 days, Monday to Saturday), at an intensity of 1.0 mW/cm 2 .
- the amount of irradiation was 60 mJ/cm 2 during only the first week after the start of the irradiation, and 120 mJ/cm 2 from the second week onward.
- UVB was ultraviolet with a wavelength from 280 to 315 nm.
- Transepidermal water loss (TEWL) after 4 weeks and 7 weeks of UVB irradiation was measured with a Tewameter, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate skin barrier functionality. Three areas on the back of each mouse were measured, and the average value was calculated. A larger TEWL value means lower skin barrier functionality (functions that prevent foreign matter outside the skin from penetrating into the body, and that prevent moisture inside the body from escaping to the outside).
- Fig. 8 shows the results of measuring TEWL after 4 weeks and 7 weeks of UVB irradiation. The results reveal that oral administration of Sample No. 10, which is a water extract of fish cartilage, reduces the TEWL value and improves skin barrier functionality.
- Hairless mice Hr-/Kud, male (Kyudo Co., Ltd.) were used for the experiment.
- mice were placed in five feeding cages, as shown in Table 4, to be divided into groups (Groups 1 to 5)(six mice in one group).
- groups Groups 1 to 5
- the subjects were marked on their tail portion to be individually identified. They continued to be preliminarily fed until the start of analysis.
- Evaluation materials were individually dissolved in water to 0.2 mg/mL to prepare administration samples.
- UVB irradiation started 3 weeks after the start of the oral administration.
- the mice were placed in a cage for UVB irradiation.
- the cage was placed into a UVB irradiation device to carry out UVB irradiation 6 times per week (once a day for 6 days, Monday to Saturday), at an intensity of 1.0 mW/cm 2 .
- the amount of irradiation was 60 mJ/cm 2 during only the first week after the start of the irradiation, and 120 mJ/cm 2 from the second week onward.
- UVB was ultraviolet with a wavelength from 280 to 315 nm.
- erythema values after 4 weeks and 7 weeks of UVB irradiation were measured with a Mexameter, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate anti-inflammation. Five areas on the back of each mouse were measured, and the average value was calculated. Inflammation due to UVB irradiation causes erythema. Thus, a larger erythema value means severer inflammation.
- Fig. 9 shows the results of measuring erythema values after 4 weeks and 7 weeks of UVB irradiation. From the results, it was found that oral administration of the water extract of fish cartilage used reduces erythema, and thus reduces inflammation caused by ultraviolet irradiation.
- PG-1 extract high molecular weight proteoglycan having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ) exhibits a large effect among the proteoglycans contained in the water extract of fish cartilage.
- Transepidermal water loss (TEWL) after 4 weeks and 7 weeks of UVB irradiation was measured with a Tewameter, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate skin barrier functionality. Three areas on the back of each mouse were measured, and the average value was calculated. A larger TEWL value means lower skin barrier functionality (functions that prevent foreign matter outside the skin from penetrating into the body, and that prevent moisture inside the body from escaping to the outside).
- Fig. 10 shows the results of measuring TEWL after 4 weeks and 7 weeks of UVB irradiation. The results reveal that oral administration of the water extract of fish cartilage used reduces the TEWL value and improves skin barrier functionality.
- Stratum corneum water content after 4 weeks and 7 weeks of UVB irradiation was measured with a Corneometer, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate skin water retention ability. Ten areas on the back of each mouse were measured, and the average value was calculated.
- Fig. 11 shows the results of measuring TEWL after 4 weeks and 7 weeks of UVB irradiation. From the results, it was found that oral administration of the water extract of fish cartilage used increases stratum corneum water content and improves skin water retention ability.
- proteoglycan (PG-1 extract) having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ) exhibits a large effect among the proteoglycans contained in the water extract of fish cartilage.
- the skin of the inner forearm and the upper inner arm of each subject was irritated with a chamber impregnated with sodium dodecyl sulfate (SLS) by the method described below, and changes after the irritation in the erythema disappearance rate (measured at the forearm) and in transepidermal water loss (TEWL) (measured at the upper arm) were compared. (The details of the test method are described below.)
- Sample No. 10 500 mg used for the test group was inserted into six hard capsules, and crystalline cellulose powder (Ceolus (registered trademark) FD-301 (produced by Asahi Kasei Chemicals Corp.)) (500 mg) used as a placebo was inserted into six hard capsules. Each of them was orally administered to their respective subjects twice a day at a rate of three capsules each time (i.e., the daily intake was 500 mg). Sample No. 10 was orally administered to seven subjects, and the placebo was orally administered to seven subjects.
- Sample No. 10 contained about 80 mg of proteoglycan having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ). This value (about 80 mg) was determined as follows. Fractions (Nos. 16 to 23) that correspond to proteoglycan having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ) in the uronic acid amount chromatogram of Sample No. 10 in Fig. 4 were collected, dialyzed, and freeze-dried to measure the dry weight thereof. The ratio of the dry weight to the amount (4 mg) of Sample No. 10 applied in the column for preparing the chromatogram in Fig. 4 was determined, and 500 mg was multiplied by this ratio to obtain the above value.
- a chamber impregnated with SLS was applied to the skin of the inner forearm and the upper inner arm of each subject to irritate the skin.
- the color of erythema on the forearm after the irritation (value a* in the L*a*b* color system) and the transepidermal water loss (TEWL) value of the upper arm after the irritation were measured at the irritated site and the non-irritated site of the arm.
- the relative value (control ratio) of the measured value of the irritated site to the measured value of the non-irritated site was calculated to examine changes in the erythema disappearance rate and in TEWL. The results are shown in Figs. 12 and 13 .
- the skin irritation and the measurement were performed as follows.
- each subject was in a constant temperature, constant humidity room at 22°C with a relative humidity of 60% for 15 minutes or more. Subsequently, a chamber (200 large Finn Chambers on Scanpor, Norgeplaster Ltd.) with filter paper impregnated with 30 ⁇ L of 0.5% SLS (sodium dodecyl sulfate: Wako Pure Chemical Industries, Ltd., Lot. STQ8638) was applied to the skin on the inner arm of each subject to expose the skin to irritation under occlusion for 4 hours.
- SLS sodium dodecyl sulfate: Wako Pure Chemical Industries, Ltd., Lot. STQ8638
- FD samples freeze-dried samples
- FD samples freeze-dried samples
- FD samples freeze-dried samples
- 100°C extraction FD sample 90°C extraction FD sample
- 70°C extraction FD sample 70°C extraction FD sample
- 50°C extraction FD sample a freeze-dried sample was obtained by heating a mixture of the small pieces of defatted salmon nasal cartilage and purified water at 100°C for 3 hours and then further for 3 hours and performing centrifugation and freeze drying in the same manner.
- This sample may be hereinafter referred to as a 100°C (3h) extraction FD sample.
- the percentage of the component having a molecular weight of not less than 5,000,000 (500 ⁇ 10 4 ), the percentage of the component having a molecular weight of not less than 2,500,000 (250 ⁇ 10 4 ), and the percentage of the component having a molecular weight of not less than 1,800,000 (180 ⁇ 10 4 ) were determined from each uronic acid amount chromatogram. The results are shown in Table 5.
- the samples were analyzed for cell proliferation ability as follows. Specifically, in a culturing dish for each sample, human skin fibroblasts (HDF53: Cell Applications, Inc.) were seeded at 1.5 ⁇ 10 4 cells in minimum essential medium (MEM) containing 10% fetal bovine serum (FBS). Each sample was filter-sterilized with a 22- ⁇ m filter and added individually to MEM to a concentration of 20 ⁇ g/mL. After the addition, the cells were cultured for five days. Following the culture, the MEM was removed, and the cells were detached and suspended with Trypsin-EDTA (Invitrogen). Thereafter, Trypan blue stain was added, and the number of cells was counted using a counting chamber.
- MEM minimum essential medium
- FBS fetal bovine serum
- the results are shown in Fig. 14 .
- the 90°C extraction FD sample significantly promoted cell proliferation compared to the control.
- the 70°C extraction FD sample and the 100°C extraction FD sample also showed a tendency to promote cell proliferation.
- the number of samples (n) was 11 for the control, 3 for the 50°C extraction FD sample, 6 for the 70°C extraction FD sample, 11 for the 90°C extraction FD sample, 6 for the 100°C extraction FD sample, 6 for the 100°C (3 h) extraction FD sample, and 5 for commercially available product A. Student's t-test was used for statistical processing.
- each sample used for the analysis was analyzed. Analysis of each component was performed as follows. For measurement of amounts of protein, lipid, ash, moisture, and hydroxyproline (used for measuring the amount of collagen), the samples were submitted to Japan Food Research Laboratories to have analysis conducted on components per 100 g of each sample. The amount of protein was measured by the Kjeldahl method, the amount of lipid was measured by the acid hydrolysis method, the amount of ash was measured by the direct ashing method, the amount of moisture was measured by the normal-pressure heat-drying method, and the amount of hydroxyproline was measured by automatic amino acid analysis (HPLC method). The amount of carbohydrate was calculated by subtracting the amounts of protein, lipid, ash, and moisture from 100 (g).
- the amount of protein was measured by the Kjeldahl method, which uses the amount of nitrogen as an indicator. Since nitrogen derived from glycosaminoglycan is also measured, adjustment was carried out as follows.
- the amount of the acidic saccharide component (in terms of chondroitin sulfate) was calculated from the amount of uronic acid determined by the carbazole-sulfuric acid method. (Specifically, the amount of uronic acid was multiplied by a conversion factor of 2.593). Since nitrogen derived from chondroitin sulfate corresponds to 2.9% of molecular weight, the obtained amount of the acidic saccharide component was multiplied by 2.9% to calculate nitrogen derived from glycosaminoglycan.
- the nitrogen obtained by subtracting nitrogen derived from glycosaminoglycan includes nitrogen derived from collagen and nitrogen derived from protein other than collagen. Since the "protein factor" of collagen is different from that of the other protein, it is necessary to ascertain the amount of nitrogen derived from collagen and the amount of nitrogen derived from the other protein.
- Collagen was quantified by quantifying "hydroxyproline,” which is an amino acid specifically present in collagen, as described above. More specifically, collagen content was determined by measuring hydroxyproline (Hyp), which is an amino acid specifically present in collagen, and assuming that collagen contains 6.7% Hyp. The thus-obtained amount of collagen was divided by 5.55, which is the protein factor of collagen, to calculate the amount of nitrogen derived from collagen.
- the amount of nitrogen derived from glycosaminoglycan and the amount of nitrogen derived from collagen were subtracted from the quantified value of nitrogen determined by the Kjeldahl method, and the value obtained by the subtraction was multiplied by 6.25, which is the protein factor of general protein, to calculate the amount of protein other than collagen.
- the amount of protein was calculated by adding the amount of collagen to the amount of protein other than collagen determined as described above.
- Table 6 The results are shown in the following Table 6.
- the values in Table 6 represent grams per 100 g of extraction FD sample.
- Table 6 also shows the amount of proteoglycan having a molecular weight of not less than 1,800,000 (180 ⁇ 10 4 ).
- the amount of proteoglycan having a molecular weight of not less than 1,800,000 (180 ⁇ 10 4 ) was obtained by multiplying the amount of glycosaminoglycan listed in Table 6 by the percentage of the component having a molecular weight of not less than 1,800,000 (180 ⁇ 10 4 ) listed in Table 5.
- the expression "10% EtOH treatment ⁇ 90°C extraction FD" in Table 6 refers to a sample obtained by defatting fish cartilage with 10% ethanol and then performing extraction with water at 90°C. More specifically, to 500 g of the small pieces of frozen salmon nasal cartilage, a 10% EtOH solution was added in an amount 2.5 times that of the small pieces, and the mixture was stirred with a stirrer at room temperature for 24 hours and centrifuged at 8,000 rpm at 4°C for 30 minutes.
- the collected insoluble matter (residue containing cartilage) was heated until the cartilage was completely dissolved through extraction at 90°C with propeller stirring, and then centrifugation and filtration were performed in the same manner as in the FD samples shown in Table 5 to obtain the freeze-dried (FD) sample.
- the protein contained in the water extract of fish cartilage according to the present invention is collagen. Further, in particular, it can be seen that the smaller the lipid content or ash content is, the more the water extract of fish cartilage has cell proliferation ability (i.e., exhibits the cell proliferation promoting effect). It is believed that the water extract of fish cartilage having cell proliferation ability more efficiently provides the inflammation alleviation effect or anti-aging effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Materials Engineering (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention relates to an extract of aquatic animal cartilage. More specifically, the present invention relates to an aquatic animal cartilage extract containing a proteoglycan having a high molecular weight.
- Proteoglycan is one of the major biological macromolecules for forming the substrate of the extracellular matrix of connective tissue, as are collagen and others. Proteoglycan was hitherto obtained by being extracted and isolated from mammal cartilage (in particular, bovine cartilage). However, ever since the occurrence of bovine spongiform encephalopathy (BSE) was reported, the use of bovine cartilage has been avoided. Thus, there has been a need for an alternative source of proteoglycan, and a production method for the alternative source. In addition, since the production cost for proteoglycan is very high due to the complexity of the existing proteoglycan extraction step and the low yield, industrial application of proteoglycan has not been fully accomplished. Thus, there has been a need for a simpler method ensuring a greater yield.
- As an alternative source for proteoglycan, aquatic animal tissue is attracting attention. Therefore, there have been attempts to extract proteoglycan from cartilage of aquatic animals, such as whales and sharks. However, due to catch restrictions placed on these aquatic animals, it has been difficult to produce a large amount of proteoglycan. Moreover, the extraction and isolation of proteoglycan is complicated, and some solvents, etc., used for extraction have high toxicity.
- Under such circumstances, there have been attempts to extract proteoglycan from the large amount of discarded aquatic animal tissues. For example,
Patent Document 1 discloses a method for producing a composition (nasal cartilage powder) containing proteoglycan from salmon nasal cartilage by using ethanol. - Patent Document 1:
JP2009-173702A - An object of the present invention is to efficiently extract proteoglycan from aquatic animal tissues.
- Surprisingly, the inventors of the present invention found a method of extracting proteoglycan from fish cartilage, which is aquatic animal cartilage, by using water. Moreover, the inventors further found that the fish cartilage water extract extracted from fish cartilage through this method contains proteoglycan of a molecular weight higher than that of the proteoglycan contained in the fish cartilage extracts obtained through hitherto known methods; further, they found that, the high molecular weight proteoglycan has a superior effect. After several attempts to further improve the extract based on these findings, the inventors completed the present invention.
- Specifically, the present invention encompasses the inventions in the following items.
-
Item 1
A water extract of fish cartilage comprising a proteoglycan having a molecular weight of not less than 1,800,000 (180×104). -
Item 2
The water extract of fish cartilage according toItem 1, comprising a proteoglycan having a molecular weight of not less than 2,500,000 (250×104). -
Item 3
The water extract of fish cartilage according toItem 2, comprising a proteoglycan having a molecular weight of not less than 5,000,000 (500×104). -
Item 4
The water extract of fish cartilage according toItem 3, comprising, on a dry mass basis, 9 mass% or more of a proteoglycan having a molecular weight of not less than 5,000,000 (500×104). - Item 5-1
The water extract of fish cartilage according to any one ofItems 1 to 4, comprising, on a dry mass basis, 30 mass% or more of collagen. - Item 5-2
The water extract of fish cartilage according to any one ofItems 1 to 5-1, wherein the proteoglycan having a molecular weight of not less than 2,500,000 (250 × 104) contains uronic acid in an amount of not less than 10% based on the total amount of uronic acid in the extract. - Item 5-3
The water extract of fish cartilage according to any one ofItems 1 to 5-2, wherein the amount of uronic acid in the extract is, on a dry mass basis, not less than 10 mass% based on the entire extract. - Item 6-1
The water extract of fish cartilage according to any one ofItems 1 to 5, wherein the fish is salmon or trout. - Item 6-2
The water extract of fish cartilage according to any one ofItems 1 to 6-1, wherein the cartilage is nasal cartilage. - Item 7-1
A composition for external use or an oral composition containing the water extract of fish cartilage according to any one ofItems 1 to 6-2. - Item 7-2
A food/drink composition, an oral composition, or a cosmetic composition containing the water extract of fish cartilage according to any one ofItems 1 to 6-2. - Item 8-1
The composition according to Item 7-1 or 7-2, for use in alleviation of inflammation or anti-aging. - Item 8-2
The water extract of fish cartilage according to any one ofItems 1 to 6-2, for use in alleviation of inflammation or anti-aging. - Item 9-1
The water extract of fish cartilage according to any one ofItems 1 to 6-2, wherein the water extract is extracted using 70°C to 100°C water. - Item 9-2
The water extract of fish cartilage according to Item 9-1, wherein the water extract is extracted using 70°C to 100°C water for 3 to 4 hours. - Item 10-1
An isolated proteoglycan having a molecular weight of not less than 5,000,000 (500×104). - Item 10-2
An isolated fish-cartilage-derived proteoglycan having a molecular weight of not less than 5,000,000 (500×104). - The fish cartilage water extract of the present invention contains proteoglycan of a molecular weight higher than that of the proteoglycan contained in the fish cartilage extracts obtained through hitherto known methods. Further, the fish cartilage water extract of the present invention has a superior anti-aging effect (in particular, anti-inflammatory effect, skin barrier functionality improving effect, and skin water-retention ability improving effect). Moreover, the fish cartilage water extract of the present invention provides these effects not only through application to skin, but also through oral administration.
-
-
Fig. 1a is a photo of a frozen salmon nasal cartilage block placed in a tray. -
Fig. 1b is a photo of small pieces of frozen salmon nasal cartilage placed in a plastic bag. -
Fig. 1c is a photo of defatted salmon nasal cartilage powder placed in a plastic bag. -
Fig. 2 is a graph showing change in yield of proteoglycan over time when water was added to small pieces of frozen salmon nasal cartilage, and extraction was performed at 100°C. The yield is the value per gram of the frozen salmon nasal cartilage. -
Fig. 3 is a graph showing a comparison of the yields of uronic acid (indicated as "GlcA") and the yields of protein (indicated as "Protein") when proteoglycan is extracted from defatted salmon nasal cartilage powder ("Powder"), frozen salmon nasal cartilage blocks ("Blocks"), or small pieces of frozen salmon nasal cartilage ("Small pieces"). The yields of GlcA and protein are represented in terms of amounts extracted per 100 g of frozen salmon nasal cartilage blocks. The amount of uronic acid reflects the amount of proteoglycan. -
Fig. 4a shows a superimposition of a uronic acid amount chromatogram and a 280-nm protein amount chromatogram. The chromatograms were obtained by analyzing one example of a water extract of fish cartilage according to the present invention (Sample No. 10) by gel filtration chromatography. -
Fig. 4b shows a uronic acid amount chromatogram with the position of each fraction at which each molecular weight marker was eluted. The chromatogram was obtained by analyzing one example of a water extract of fish cartilage according to the present invention (Sample No. 10) by gel filtration chromatography. -
Fig. 5 shows a uronic acid amount chromatogram obtained by analyzing one example of a water extract of fish cartilage according to the present invention (Sample No. 10) by ion-exchange chromatography. -
Fig. 6 shows a uronic acid amount chromatogram and a 280-nm protein amount chromatogram. The chromatograms were obtained by analyzing the proteoglycan fraction ofFig. 5 by gel filtration chromatography. -
Fig. 7 shows the results of analyzing the inflammation alleviation effect obtained through oral administration of one example of a water extract of fish cartilage according to the present invention (Sample No. 10). The graph on the left shows the results after 4 weeks of UVB irradiation, and the graph on the right shows the results after 7 weeks of UVB irradiation. -
Fig. 8 shows the results of analyzing the effect of enhancing and improving skin barrier functionality, obtained through oral administration of one example of a water extract of fish cartilage according to the present invention (Sample No. 10). The graph on the left shows the results after 4 weeks of UVB irradiation, and the graph on the right shows the results after 7 weeks of UVB irradiation. -
Fig. 9 shows the results of analyzing the inflammation alleviation effect obtained through oral administration of Sample No. 10, PG-1 extract, and PG-2 extract. PG-1 extract and PG-2 extract were obtained by further purifying Sample No. 10. The graph on the left shows the results after 4 weeks of UVB irradiation, and the graph on the right shows the results after 7 weeks of UVB irradiation. -
Fig. 10 shows the results of analyzing the effect of enhancing and improving skin barrier functionality, obtained through oral administration of Sample No. 10, PG-1 extract, and PG-2 extract. PG-1 extract and PG-2 extract were obtained by further purifying Sample No. 10. The graph on the left shows the results after 4 weeks of UVB irradiation, and the graph on the right shows the results after 7 weeks of UVB irradiation. -
Fig. 11 shows the results of analyzing the effect of enhancing and improving skin water retention ability, obtained through oral administration of Sample No. 10, PG-1 extract, and PG-2 extract. PG-1 extract and PG-2 extract were obtained by further purifying Sample No. 10. The graph on the left shows the results after 4 weeks of UVB irradiation, and the graph on the right shows the results after 7 weeks of UVB irradiation. -
Fig. 12 shows the results of a clinical test for analyzing the effect of enhancing and improving skin barrier functionality, obtained through oral administration of Sample No. 10. -
Fig. 13 shows the results of a clinical test for analyzing the effect of enhancing and improving skin water retention ability, obtained through oral administration of Sample No. 10. -
Fig. 14 shows the results of a cell proliferation test when extracts extracted at heating temperatures of 50°C, 70°C, 90°C, 100°C, and 100°C (extra heating time), and commercially available product A, were individually added. The asterisk (*) refers to significance at significance level of 0.1% relative to the control. - The present invention is described in more detail below. The term "mass" in this specification is equivalent to "weight".
- Proteoglycan has a structure in which glycosaminoglycan (mucopolysaccharide) and protein are covalently bonded. Glycosaminoglycan is acidic saccharide consisting of a repeating disaccharide unit. Specifically, examples thereof include chondroitin sulfate, dermatan sulfate, and heparan sulfate. In the repeating disaccharide units of the acidic saccharide components, generally, one of the disaccharides is amino sugar, and the other is a uronic acid. Therefore, the detection of proteoglycan may be performed using a carbazole-sulfuric acid method, which is an ordinary method for detecting uronic acids.
- Further, a compound having a comb-like bond of glycosaminoglycan and protein is referred to as a proteoglycan monomer. (This protein in a proteoglycan monomer is called a core protein.) In particular, in a living body, the proteoglycan monomer is bonded to a hyaluronic acid via a link protein, thereby forming an aggregate. The aggregate is also called a proteoglycan aggregate. The term "proteoglycan" used in this specification encompasses a proteoglycan monomer and a proteoglycan aggregate. Hyaluronic acids are a kind of glycosaminoglycan.
- The fish cartilage water extract of the present invention contains a high molecular weight proteoglycan. The term "high molecular weight proteoglycan" used herein specifically refers to a proteoglycan having a molecular weight of not less than 1,800,000 (180 × 104), preferably a molecular weight of not less than 2,500,000 (250 × 104), not less than 3,500,000 (350 × 104), not less than 4,000,000 (400 × 104), not less than 5,000,000 (500 × 104), not less than 6,000,000 (600 × 104), not less than 7,000,000 (700 × 104), not less than 8,000,000 (800 × 104), not less than 9,000,000 (900 × 104), not less than 10,000,000 (1000 × 104), not less than 11,000,000 (1100 × 104), not less than 12,000,000 (1200 × 104), not less than 13,00,000 (1300 × 104), not less than 14,000,000 (1400 × 104), not less than 15,000,000 (1500 × 104) not less than 16,000,000 (1600 × 104), not less than 17,000,000 (1700 × 104), not less than 18,000,000 (1800 × 104), not less than 19,000,000 (1900 × 104), or not less than 20,000,000 (2000 × 104). A greater molecular weight is preferable. Particularly preferred is a proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104). The fish cartilage water extract of the present invention is subjected to gel filtration chromatography under the following conditions, and the uronic acid amount (reflecting a proteoglycan amount) in each fraction is determined using a carbazole-sulfuric acid method. By creating a chromatogram based on the determined uronic acid amounts, it is possible to confirm the existence of proteoglycan having the above range of molecular weight. Such a chromatogram based on the uronic acid amount may be hereinafter referred to as "uronic acid amount chromatogram". Further, it is also possible to make a chromatogram based on the absorbencies by measuring absorbencies of the fractions at 280 nm, and then finding relative values of protein amounts based on the measurement results (i.e., the measurement values are assumed to be values that reflect the protein amounts). Hereinafter, such a chromatogram may be referred to as "280 nm protein amount chromatogram".
- Column: Sepharose CL-2B packed column (1-cm dia. × 50 cm column packed with Sepharose CL-2B as a carrier. Sepharose CL-2B has a dextran fractionation range of 100 to 20,000 kDa and is available from GE Healthcare and other companies. Sepharose CL-2B, CAS registry No. 65099-79-8, is a 2% crosslinked agarose with a particle size of 60 to 200 µm (measured by the laser diffraction scattering method).)
Buffer: 0.1 M phosphate buffer (pH of 7.1, containing 0.2 M NaCl) Amount of applied sample: 4 mg of water extract of fish cartilage (on a dry mass basis) (dissolved in 1 mL of buffer for use)
Flow rate: 0.15 mL/min
Amount of fraction: 1 mL/tube
Molecular weight analytical curve: The various dextran molecular weight markers described below are subjected to gel filtration chromatography under the same conditions as described above, absorbency (which reflects the amount of dextran) of each fraction is measured by the phenol-sulfuric acid method, which is a well-known method for detecting saccharide, a fraction at which each marker is eluted is determined, and an analytical curve reflecting the molecular weight of the component contained in each fraction in the gel filtration chromatography under the above conditions is prepared. The term "fraction at which each marker is eluted" refers to a fraction at which each marker is eluted most, i.e., a fraction corresponding to a peak maximum in a chromatogram reflecting the amount of dextran when each dextran molecular weight marker is subjected to gel filtration. - Dextran from Leuconostoc mesenteroides (mol wt 5,000,000 - 40,000,000)(Sigma) ... For measuring the void volume of the column, 20,000 kDa
Dextran Standard 1,400,000 (Sigma) ... 1400 kDa
Dextran Standard 670,000 (Sigma) ... 670 kDa
Dextran Standard 410,000 (Sigma) ... 410 kDa
Dextran Standard 270,000 (Sigma) ... 270 kDa - The dextran from Leuconostoc mesenteroides is used as a marker after pretreatment is carried out to remove low molecular weight dextran contained in the marker. The pretreatment is performed by eluting dextran from Leuconostoc mesenteroides under the conditions described above in "Gel Filtration Chromatography Conditions" and collecting and freeze-drying fractions having a molecular weight of not less than 20,000 kDa. More specifically, fractions that correspond to a peak that first appears in a chromatogram reflecting the amount of dextran are collected and freeze-dried. The chromatogram is prepared by measuring absorbency of each fraction by the phenol-sulfuric acid method. (It is believed that dextran having a molecular weight of not less than 20,000 kDa is obtained by collecting and freeze-drying such fractions.) This freeze-dried product is actually used as a marker (for measuring the void volume of the column).
- Measurement of absorbency to obtain a chromatogram reflecting the amount of dextran is performed according to the method (the phenol-sulfuric acid method) described in Hodge, J. E., and Hofreiter, B. T., Method in Carbohydrate Chemistry, 1, 338 (1962). More specifically, the measurement is carried out as follows.
- [1] 500 µL of a sample aqueous solution is placed in a 105 × 15 mm test tube.
- [2] 500 µL of a phenol reagent (5 v/v% aqueous phenol solution) is added thereto, and the mixture is stirred.
- [3] 2.5 mL of concentrated sulfuric acid is added thereto, and immediately the mixture is stirred vigorously for 10 seconds.
- [4] The mixture is left to stand for 20 minutes or more at room temperature.
- [5] The absorbency at 490 nm is measured with a spectrophotometer.
- The carbazole-sulfuric acid method refers to a well-known method performed by adding a carbazole solution, which is a color component of uronic acid (glucuronic acid (Glc A), iduronic acid, etc.), to a measurement specimen, and measuring the absorbency by using a spectrophotometer, thereby finding uronic acid amount based on the absorbency. An analytical curve is plotted using the glucuronic acid standard solution having a specific concentration, thereby finding the glucuronic acid content in the specimen. More specifically, the carbazole-sulfuric acid method is performed as follows. 2.5 ml of a reagent obtained by dissolving 0.95 g of sodium borate decahydrate in 100 ml of a concentrated sulfuric acid is placed in a test tube and ice-cooled. 0.5 ml of a test object (preferably containing 2 to 20 µg of uronic acid) is gently layered thereon. The mixture is stirred well while being ice-cooled, thereby keeping it at room temperature or below. After the test tube is covered with a glass ball, the test tube is heated in a boiling water bath for 10 minutes, followed by water cooling to decrease the temperature to room temperature. Then, 0.1 ml of a reagent obtained by dissolving 125 mg of carbazole in 100 ml of anhydrous methyl alcohol is added and mixed therewith, and the mixture is heated in a boiling water bath for 15 minutes. Thereafter, the mixture is water-cooled to room temperature, and the absorbency at 530 nm is measured. In the blank test, 0.5 ml of distilled water is used. Simultaneously, an analytical curve is plotted using a glucuronic acid. (The carbazole-sulfuric acid method in the Examples described below is performed in the same manner as above.)
- It is preferable that, on a dry mass basis, at least 10 mass% of the total amount of the uronic acid amount (determined by the carbazole-sulfuric acid method) of the fish cartilage water extract of the present invention is derived from proteoglycan having a molecular weight of not less than 2,500,000 (250 × 104). In other words, on a dry mass basis, the uronic acid amount of a proteoglycan having a molecular weight of not less than 2,500,000 (250 × 104) is preferably at least 10 mass% based on the total uronic acid amount of the fish cartilage water extract of the present invention. Further, the uronic acid amount is more preferably not less than 15 mass%, not less than 20 mass%, not less than 25 mass%, not less than 30 mass%, not less than 35 mass%, not less than 40 mass%, not less than 45 mass%, not less than 50 mass%, not less than 55 mass%, or not less than 60 mass%. The greater the mass%, the more desirable. Further, a uronic acid amount of proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104) is preferably at least 7 mass% based on the total uronic acid amount of the fish cartilage water extract of the present invention. Further, the uronic acid amount of proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104) is more preferably not less than 10 mass%, not less than 13 mass%, not less than 16 mass%, not less than 20 mass%, not less than 24 mass%, not less than 27 mass%, not less than 30 mass%, not less than 34 mass%, not less than 37 mass%, or not less than 40 mass%. The greater the mass%, the more desirable.
- The proportion of the uronic acid amount of a proteoglycan having a molecular weight of not less than a specific value (which is expressed as X hereinbelow) based on the total uronic acid amount in the extract can be found from a peak area in the aforementioned uronic acid amount chromatogram. More specifically, the proportion can be found by calculating a proportion of the area of a uronic acid having a molecular weight of not less than X based on the entire peak area of the uronic acid amount chromatogram. Even more specifically, on a uronic acid amount chromatogram in which the vertical axis denotes uronic acid amounts and the horizontal axis denotes the fraction number, a vertical line is drawn so that the vertical line passes through the fraction containing the proteoglycan having a molecular weight X; and then, from the two peak areas divided by the vertical line, a peak area containing proteoglycan of a greater molecular weight is determined and the proportion of the peak area based on the total peak area is found.
- Further, the uronic acid amount (measured by the carbazole-sulfuric acid method) contained in the fish cartilage water extract of the present invention is, on a dry mass basis, preferably not less than 5 mass%, more preferably not less than 10 mass%, even more preferably not less than 15 mass%, still more preferably not less than 20 mass%, particularly preferably not less than 25 mass%. In the present specification (in particular, figures and tables), the term "GlcA" may be used as an abbreviation for glucuronic acid (e.g., "GlcA(µg)")
- Further, the fish cartilage water extract of the present invention preferably contains proteoglycan having a molecular weight of not less than 1,800,000 (180 × 104) in an amount of, on a dry mass basis, not less than 30 mass%, more preferably not less than 35 mass% of the extract.
- Further, the fish cartilage water extract of the present invention preferably contains proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104) in an amount of, on a dry mass basis, not less than 5 mass%, not less than 10 mass%, not less than 15 mass%, not less than 20 mass%, not less than 25 mass%, not less than 30 mass%, or not less than 35 mass% of the extract. A greater proportion is more desirable.
- Further, the fish cartilage water extract of the present invention contains only a small amount of lipid. The mass ratio of lipid to proteoglycan (lipid amount/proteoglycan amount) in the fish cartilage water extract of the present invention is preferably smaller than the mass ratio of lipid to proteoglycan (lipid amount/proteoglycan amount) in fish cartilage used as the raw material of the extract. The lipid content in the fish cartilage water extract of the present invention is, on a dry mass basis, preferably not more than 5 mass%, more preferably not more than 4 mass%, even more preferably not more than 3 mass%, still more preferably not more than 2 mass%, particularly preferably not more than 1 mass%. As described below, such a fish cartilage water extract can be obtained by using defatted fish cartilage (fish cartilage from which lipid is removed). Further, the fish cartilage water extract may also be obtained by defatting the resulting extract using a known defatting method.
- Further, most of the protein contained in fish cartilage extract of the present invention is preferably collagen (preferably type II collagen). More specifically, preferably not less than 80 mass%, more preferably not less than 85 mass% of the protein is collagen. The amount of collagen in the fish cartilage extract of the present invention is, on a dry mass basis, preferably not less than 30 mass%, more preferably 30 to 60 mass%.
- Further, the ash content in the fish cartilage extract of the present invention is, on a dry mass basis, preferably not more than 15 mass%, more preferably 5 to 15 mass%, even more preferably 5 to 10 mass%.
- The protein amount above is found by measuring the nitrogen amount in the sample using the Kjeldahl method, and subtracting the glycosaminoglycan-derived nitrogen amount from the above nitrogen amount; i.e., the protein amount is the amount excluding the amount of proteoglycan-derived protein. Further, the ash content is found by the direct ashing method. Further, the collagen amount is found by measuring the hydroxy proline amount in the sample using the automatic amino acid analysis (HPLC method), and calculating the collagen amount assuming that the collagen contains 6.7% hydroxy proline.
- The fish cartilage water extract of the present invention is extracted from fish cartilage, preferably from Oncorhynchus (Salmonidae) cartilage, including trout (humpback salmon, cherry salmon, satsukimasu salmon, etc.), salmon (chum salmon, sockeye salmon, silver salmon, chinook salmon, steelhead, etc.), shark, and cod. Salmon and trout are particularly preferable. The cartilage to be used is not particularly limited; however, head cartilage, in particular, nasal cartilage, is preferable. Moreover, since fish (in particular, salmon and trout) heads are usually discarded when fish is processed into food products, the cost of fish heads is low, and a large amount of fish heads can be stably supplied.
- The extraction is performed using water. It is possible to subject fish cartilage obtained from a biological sample to extraction as it is; however, the fish cartilage may also be subjected to extraction after being pulverized (more specifically, pulverized into small pieces or powder). Further, as described below, it is also possible to subject fish cartilage to a defatting treatment using ethanol or the like before the extraction. As such, proteoglycan (including a high molecular weight proteoglycan) can be extracted using water. More specifically, the fish cartilage water extract of the present invention is preferably extracted from fish cartilage by using water. It is also possible to perform water extraction while heating water, or by using hot or boiling water. With this method, a fish cartilage water extract with a greater effect can be efficiently obtained.
- The small pieces of fish cartilage are obtained by pulverizing fish cartilage into small pieces. The pulverization may be performed using a known method. For example, the pulverization of fish cartilage (preferably frozen fish cartilage) into small pieces may be performed using known devices such as a blender or a mill. The pulverization is preferably performed at a low temperature. For example, the pulverization is preferably performed at a temperature at which the pulverized fish cartilage can be kept frozen. More specifically, the pulverization is preferably performed at a temperature of 0°C or less.
- Further, in terms of efficiency in extraction, it is preferable to use small frozen pieces of fish cartilage. The small frozen pieces of fish cartilage can be obtained by (i) freezing fish cartilage and then pulverizing it into small pieces, or by (ii) pulverizing fish cartilage into small pieces and then freezing it. The small frozen pieces of fish cartilage obtained by method (i) are more preferable. The freezing method is not particularly limited, and any known freezing method can be used. For example, a method of storing fish cartilage in a freezer at about -20 to -80°C for about 24 to 72 hours can be used.
- The small pieces of fish cartilage or small frozen pieces of fish cartilage are preferably about 0.001 to 0.5 g, more preferably about 0.005 to 0.3 g, even more preferably about 0.01 to 0.1 g per piece. The pulverization of fish cartilage into small pieces is preferably performed in a manner enabling production of such small pieces. (The conditions for obtaining such small pieces can be easily obtained by appropriately selecting and adjusting the device to be used.)
- The fish cartilage powder is obtained by pulverizing fish cartilage into powder (powdered fish cartilage). The pulverization may be performed using a known method. For example, the pulverization of fish cartilage (preferably frozen fish cartilage) into powder may be performed using known devices such as a blender or a mill. The pulverization is preferably performed at a low temperature (e.g., not more than 0°C).
- Further, in terms of efficiency in extraction, it is preferable to use frozen fish cartilage powder. The frozen fish cartilage powder can be obtained by (i') freezing fish cartilage and then pulverizing it into powder, or by (ii') pulverizing fish cartilage into powder and then freezing it. The frozen fish cartilage powder obtained by method (i') is more preferable. The freezing method is not particularly limited, and any known freezing method can be used. For example, a method of storing fish cartilage in a freezer at about -20 to -80°C for about 24 to 72 hours can be used.
- The term "powder" refers to a piece smaller than what is referred to by the term "small pieces"; however, these terms are not necessarily distinguished clearly. Among the products resulting from pulverization of fish cartilage, relatively large pieces are referred to as "small pieces", and relatively small pieces are referred to as "powder". Therefore, although it is not particularly limited, powder preferably contains particles having a particle size of about 10 to 1000 µm, preferably about 50 to 500 µm, more preferably about 100 to 200 µm (measured by a laser diffraction and scattering method). However, the particle size is not particularly limited to these ranges. The powder preferably contains particles having the above particle size in a large proportion (e.g., not less than 50 mass%, preferably not less than 70 mass%).
- Small defatted pieces of fish cartilage or fish cartilage powder (small fish cartilage pieces or powder from which lipid is removed) may also be used. In other words, small defatted fish cartilage pieces or defatted fish cartilage powder may also be used. By using defatted fish cartilage, a highly purified fish cartilage water extract that incorporates less lipid can be obtained. The small defatted fish cartilage pieces or defatted fish cartilage powder can be obtained by (α) pulverizing defatted fish cartilage into small pieces or powder, or by (β) pulverizing the fish cartilage into small pieces or powder and then defatting the small pieces or powder.
- The defatting may be performed by a known method. For example, fish cartilage defatting step (α) above may be performed by a method of running fish cartilage under water (e.g., tap water) for about 1 to 24 hours. Preparation of fish cartilage can be performed using a known method, including a method of immersing fish tissues (preferably a fish head) in water for about 1 to 24 hours to make the tissue swell, and removing tissues other than cartilage (preferably nasal cartilage), and a method of thawing a frozen salmon head, then immediately separating the nasal cartilage and running the nasal cartilage under water for about 1 to 24 hours, thereby washing and defatting the cartilage. If the cartilage has residual flesh, it is preferable to remove the flesh with tweezers or the like. At this point, since the fish cartilage has not been pulverized into small pieces or powder, it is likely that little proteoglycan will be extracted even after running the cartilage under water. Further, as in step (β) below, lipid can be removed using an organic solvent.
- Further, for example, the method for defatting the small fish cartilage pieces or fish cartilage powder in step (β) above may be performed by extracting and removing lipid using an organic solvent. Examples of the organic solvents include ethanol, hexane, acetone, and the like. More specifically, as step (β), a method disclosed in Patent Document 1 (
JP2009-173702A Patent Document 1 also discloses more detailed conditions.) - A. Frozen aquatic animal tissues (fish tissues) are crushed and treated at 0 to 20°C, pH of 4.8 to 7, after adding water.
- B. A solid-liquid mixture obtained by step (A) is centrifuged to remove the uppermost lipid layer and the middle aqueous layer, thereby collecting a precipitate.
- C. The precipitate is dried and pulverized into powder.
- D. A solvent, namely, hexane, acetone or ethanol, is added to the obtained dried powder to extract and remove residual lipid.
- E. The solvent is removed.
- In addition, it is more preferable to use small frozen and defatted fish cartilage pieces or fish cartilage powder (small frozen and defatted fish cartilage pieces or frozen and defatted fish cartilage powder). These can be obtained, for example, by freezing defatted fish cartilage and pulverizing the frozen fish cartilage into small pieces or powder.
- The fish cartilage, preferably small fish cartilage pieces, or fish cartilage powder (which hereinafter may be referred to collectively as "fine fish cartilage"), is subjected to water extraction. Examples of water used for water extraction (which hereinafter may be referred to as "extraction water") include Milli-Q water, distilled water, deionized water, purified water, and tap water. Further, the pH of the extraction water is generally about 5.5 to 8.0, preferably about 6.0 to 7.5, more preferably about 6.5 to 7.5. It is not preferable to dissolve substances that greatly change the pH, such as acids, alkalis, bases, and the like. If an acid compound such as organic acid or inorganic acid, or an alkali compound such as sodium hydroxide, is added to the extraction water, a high molecular weight proteoglycan (in particular, a high molecular weight proteoglycan having a molecular weight of 10,000,000 (1000 × 104)) is reduced or disappears; thus, it is not preferable to add acid compounds or alkali compounds. Although a restrictive interpretation is not desired, this is presumably because acid compounds and alkali compounds cause degradation of proteoglycan aggregates during extraction.
- The water extract can be obtained, for example, by immersing fish cartilage in water for an appropriate amount of time (e.g., not less than 30 minutes, preferably about 30 minutes to 24 hours, more preferably about 1 to 12 hours, even more preferably about 2 to 6 hours, still more preferably about 3 to 4 hours). The amount of water is not particularly limited; for example, the water amount is a sufficient amount for completely immersing all the small fish cartilage pieces or fish cartilage powder subjected to extraction in water. The fish cartilage pieces or powder may be allowed to stand still; more preferably it may be stirred. Further, the water temperature during the extraction is not particularly limited; however, the temperature is preferably not less than 50°C, more preferably not less than 70°C. To ensure this temperature range, the water may be heated during the extraction or before the extraction. The heating temperature (i.e., the temperature of the water used) is preferably about 50 to 100°C, more preferably about 70 to 100°C, even more preferably about 80 to 100°C. The heating may be performed under an increased pressure. Since heating may cause degradation of high molecular weight proteoglycan, the heated extraction water may be replaced during the extraction. The interval between replacements of extraction water is, for example, every 15 minutes to 4 hours, preferably every 30 minutes to 2 hours, or about 1 hour. As a preferable method, a method of adding water (preferably heated water) to fish cartilage in a sufficient amount for completely immersing the total amount of fish cartilage, and allowing it to stand or stirring it for 3 to 4 hours while heating may be used. Another preferable method is repeatedly performing a process of adding water (preferably heated water) to fish cartilage in a sufficient amount for completely immersing the total amount of fish cartilage, allowing it to stand for an hour while heating, and collecting the resulting water. (In this case, the water extraction takes 4 hours in total.)
- After the water extraction, the liquid portion is collected to obtain a fish cartilage water extract. The collection of the liquid portion is performed by removing the supernatant through, for example, a centrifugation treatment (e.g., centrifugation at 5000 rpm, 4°C, for 20 minutes) or a continuous centrifugation treatment. The liquid (supernatant) may be used, as it is, as the fish cartilage water extract of the present invention, or it may further be purified by a known method (e.g., defatting). It is also possible to concentrate the liquid by distillation under reduced pressure or the like. It is also possible to dry or powderize the liquid according to the freeze-drying method or the spray drying method. The fish cartilage water extract of the present invention thus obtained may be used as, for example, materials for food, cosmetics, oral compositions, medicinal products, and the like.
- The fish cartilage water extract of the present invention may be suitably used for, in particular, skin anti-aging. Skin is constantly exposed to various kinds of damage. For example, in the dermal layer, the epidermis barrier functionality decreases due to external factors (e.g., light irradiation such as ultraviolet) or internal factors (e.g., aging). Such damage causes an increase in transepidermal water loss (TEWL), thereby causing dry skin, rough skin or the like. Further, for the same reason, a decrease in the ability to produce collagen, a decrease in skin elasticity, or thickening of the dermis may occur in the dermal layer, thereby furthering hardening of the skin. This may result in wrinkles or the like.
- The fish cartilage water extract of the present invention exhibits various effects (anti-inflammatory effect, skin barrier functionality improving effect, skin water-retention ability improving effect, and cell proliferation promoting effect) to inhibit or alleviate such skin symptoms. In particular, the fish cartilage water extract of the present invention is suitable to prevent or alleviate these skin symptoms caused by light irradiation (exposure) (in particular, ultraviolet irradiation). The degree of the cell proliferation promoting effect varies depending on the temperature during water extraction. This is presumably because the temperature change during water extraction changes the composition of the fish cartilage water extract.
- The usage of the fish cartilage water extract of the present invention is not limited; however, since the fish cartilage water extract of the present invention provides the aforementioned effects through embrocation or oral administration, the fish cartilage water extract of the present invention is suitable for compositions for external use or oral compositions. More specifically, the fish cartilage water extract of the present invention is preferably used as a composition for external use or an oral composition. These compositions may be used as a medicinal composition, a quasi-drug composition, an oral composition, a cosmetic composition, a food composition, and the like. They may be produced by a standard method using the fish cartilage water extract of the present invention. They are particularly useful for products in the oral-care industry, skin-care industry, hair-care industry, and health-care industry.
- The oral compositions containing the fish cartilage water extract of the present invention (which may be hereinafter referred to as oral compositions of the present invention) used in the oral-care industry may be the fish cartilage water extract of the present invention itself, or a composition produced by appropriately combining the fish cartilage water extract of the present invention with other components (e.g., abrasives, binders, surfactants, excipients, wetting agents, pH adjusters, thickeners, sweetening agents, preservatives, medicinal components, coloring agents, flavoring agents, and the like) generally used for oral compositions. Examples of the oral composition products include paste agents, ointments, gels, embrocations, sprays, supplements, liquids, mouthwashes, pastes, chewing gum, troches, and tablets, which may be manufactured by standard methods.
- Such oral compositions of the present invention can be preferably used for alleviation of inflammation in oral tissues, anti-aging in oral tissues, and prevention or alleviation of dryness of the oral tissues. More specifically, the oral compositions of the present invention encompass an inflammation alleviation oral composition, an anti-aging oral composition, a tissue-repairing oral composition, and an oral dryness prevention/alleviation oral composition.
- The cosmetic composition (hereinafter may be referred to as "cosmetic composition of the present invention") containing the fish cartilage water extract of the present invention used as hair-care products or skin-care products may be the fish cartilage water extract of the present invention itself, or a composition produced by appropriately combining the fish cartilage water extract of the present invention with cosmetically acceptable surfactants, wetting agents, polymeric agents, powder, esters, alcohols, plant or animal oils, medicinal agents, preservatives, coloring agents, flavoring agents, or other cosmetically acceptable components or materials using a standard method. More specifically, the cosmetic compositions produced by incorporating the fish cartilage water extract of the present invention include hair restorers, hair tonics, emulsions, lotions, creams, serums, face packs, face masks, and sunscreens. Such a cosmetic composition of the present invention may be preferably used for alleviation of inflammation, anti-aging, or moisture retention. Examples of preferable usages include compositions for hair restoration, scalp care, sun protection, sunburn care, moisturizing and anti-aging of the skin (e.g., prevention or alleviation of dry skin, rough skin, facial wrinkles, or sagging skin).
- The food and beverage compositions (beverages and food) containing the fish cartilage water extract of the present invention (which may be hereinafter referred to as food and beverage compositions of the present invention) used in the health-care industry may be the fish cartilage water extract of the present invention itself, or a composition produced by appropriately combining the fish cartilage water extract of the present invention with bases, carriers or additives that are acceptable in terms of food hygiene, or other components or materials that are used for food and beverages. Examples of these include processed food and beverages containing the fish cartilage water extract of the present invention with claimed effects of moisturizing and anti-aging of the skin (e.g., prevention or alleviation of dry skin, rough skin, facial wrinkles, or sagging skin), dietary supplements, food for special purposes (food for patients, food for specific health uses, food for patients deglutition disorder, etc.) and beauty food. Moreover, the present invention also includes moisturizers and skin anti-aging agents formed of the aforementioned food and beverage compositions of the present invention. The moisturizers and skin anti-aging agents may be supplied in the forms of drinks, pills, tablets, capsules, granules, jelly, troches, pastes, viscous liquids, powder, block bars, or the like for cosmetic or skin anti-aging purposes (e.g., prevention or alleviation of dry skin, rough skin, facial wrinkles, or sagging skin).
- The amount of the fish cartilage water extract contained in the compositions for external use or oral composition (in particular, oral compositions, cosmetic compositions, or food or beverage compositions of the present invention) containing the fish cartilage water extract of the present invention is, for example, but not limited to, generally 0.0001 to 100 mass%, preferably 0.001 to 50 mass%, more preferably 0.005 to 30 mass%, even more preferably 0.01 to 20 mass%, based on the entire composition. Further, the amount of uronic acid derived from proteoglycan having a molecular weight of not less than 2,500,000 (250 × 104) in the composition is, for example, about 0.00001 to 10 mass%, preferably about 0.0001 to 5 mass%, more preferably about 0.0005 to 1 mass%, based on the entire composition.
- Further, the present invention also encompasses methods for obtaining the various effects disclosed in this specification, including a method for alleviating inflammation on the skin or in the oral cavity, a method for enhancing or improving barrier functionality, and a method for promoting cell (in particular, fibroblast) proliferation, by applying the fish cartilage water extract of the present invention to skin or the oral cavity. These methods may be performed using the fish cartilage water extract of the present invention as it is, more preferably, using the above compositions for external use, or oral compositions or cosmetic compositions of the present invention. The target subject of the method is not particularly limited; however, the method is preferably used for subjects having inflammation or subjects having decreased skin barrier functionality due to aging or sunburn. The method may also be used not only for treatment purposes but also for cosmetic purposes. The method is particularly suitable for cosmetic purposes for enhancing barrier functions. The target subjects are preferably mammals, including humans. More specifically, non-human mammals can also be target subjects. Examples of non-human mammals include pet animals or livestock, including dogs, cats, apes, mice, rats, hamsters, rabbits, cows, horses, swine, sheep, goats, Ilamas, and camels. The application amount is also not limited, and a suitable effective amount can be determined. In particular, in application to humans, it is preferable to adjust the dosage of the fish cartilage water extract by adjusting the amount of proteoglycan, for example, so that the amount of the uronic acid derived from a high molecular weight proteoglycan having a molecular weight of not less than 2,500,000 (250 × 104) (more preferably, not less than 5,000,000 (500 × 104)) is preferably about 0.1 to 500 mg, more preferably about 0.5 to 250 mg, even more preferably about 1 to 100 mg, per adult/day.
- Furthermore, the present invention also encompasses methods for obtaining the various effects disclosed in this specification, including a method for alleviating inflammation on the skin or in the oral cavity, a method for enhancing or improving skin barrier functionality, a method for inhibiting thickened skin and a method for improving skin water retention ability, through oral administration of the fish cartilage water extract of the present invention. These methods may be performed using the fish cartilage water extract of the present invention as it is, more preferably, using the oral compositions described above, or food and beverage compositions of the present invention. Further, medicinal compositions containing the fish cartilage water extract of the present invention are also preferably used. The target subject of the method is not particularly limited; however, the method is preferably used for subjects who developed inflammation, or subjects with decreased skin barrier functionality or skin water retention ability due to aging or sunburn. The method may also be used for cosmetic purposes. The target subjects are preferably mammals including humans. More specifically, non-human mammals can also be target subjects. Examples of non-human mammals include pet animals or livestock, including dogs, cats, apes, mice, rats, hamsters, rabbits, cows, horses, swine, sheep, goats, Ilamas, and camels. The application amount is also not limited, and a suitable effective amount can be determined. In particular, in the application to humans, it is preferable to adjust the dosage of the fish cartilage water extract by adjusting the amount of proteoglycan, for example, so that the amount of the uronic acid derived from the high molecular weight proteoglycan having a molecular weight of not less than 2,500,000 (250 × 104) (more preferably, not less than 5,000,000 (500 × 104)) is about 0.2 to 1000 mg, more preferably about 1 to 800 mg, even more preferably about 2 to 500 mg, per adult/day.
- The present invention is described below in more detail. However, the scope of the invention is not limited to these Examples.
- The following three types ((1) to (3)) of samples derived from salmon nasal cartilage were used for analyzing extraction of proteoglycan. Salmon nasal cartilage used for the analysis was obtained by separating nasal cartilage immediately after thawing a frozen salmon head, washing and defatting the nasal cartilage by running it under water for 6 hours, removing pieces of flesh and the like with tweezers, and washing the nasal cartilage with water by hand.
- Salmon nasal cartilage was stored and frozen in a freezer, and the frozen nasal cartilage was used as a frozen salmon nasal cartilage block. The frozen salmon nasal cartilage block had a size of about 2.5 × 1.5 cm to about 4.5 × 2 cm and a weight of about 1.71 g to about 6.91 g. (The average weight of 7 blocks was 3.701 g.), although the size and weight depend on the size of the salmon head used.
Fig. 1a shows a photo of a frozen salmon nasal cartilage block. - Frozen salmon nasal cartilage blocks from item (1) above were placed in a blender and crushed for 10 seconds to prepare small pieces of frozen salmon nasal cartilage.
Fig. 1b shows a photo of small pieces of frozen salmon nasal cartilage. Twenty pieces were randomly collected, and the size and the mass of each piece were analyzed. Each piece had a size of about 0.2 cm to about 0.7 cm and a mass of about 0.0116 to about 0.0890 g. (The average weight of 20 pieces was 0.033 g.) From 100 g of the frozen salmon nasal cartilage blocks, 95.6 g of small pieces of frozen salmon nasal cartilage was obtained. - Defatted salmon nasal cartilage powder was prepared using frozen salmon nasal cartilage from item (1) above by the method disclosed in Example 1 of Patent Document 1 (
JP2009-173702A Fig. 1c shows a photo of defatted salmon nasal cartilage powder. - The following is an excerpt from the disclosure of Example 1 of
Patent Document 1.
"Frozen salmon nasal cartilage (100 g) was crushed, and an equal volume of tap water at 15°C was added to the crushed salmon nasal cartilage. The mixture was gently stirred to mix it thoroughly, and the mixture, which was maintained at about 5°C, was immediately centrifuged with a centrifugal separator at 9,000 rpm at 4°C for 30 minutes to separate lipid and other components including proteoglycan. Three layers were obtained after the centrifugation. The lipid layer in the upper layer and the aqueous layer in the middle layer were removed, and the precipitate was collected. The precipitate was freeze-dried and then pulverized with a centrifugal mill to prepare a water-defatted fine powder. At this stage, some of the fine powder was subjected to ether extraction for measurement of lipid, and it was found that 8.8% lipid remained, that the removal rate was 75.0% when lipid before defatting was defined as 100%, and that the lipid had faint foul odor. Subsequently, a 10-fold volume of ethanol was added to the water-defatted fine powder to dissolve and extract the lipid with the foul odor. This operation was repeated twice. The ethanol solution was filtered off and the solvent was evaporated to obtain a pale yellow-brown, odorless proteoglycan composition powder. The yield relative to the salmon nasal cartilage was 58.7% (dry basis), and the proteoglycan content was 77.7%. The foul odor of the proteoglycan composition powder completely disappeared."
The "frozen salmon nasal cartilage" of Example 1 ofPatent Document 1 corresponds to the "frozen salmon nasal cartilage blocks" described above. The term "dry basis" means a dry mass basis. - Extraction of proteoglycan was attempted by adding water to small pieces of frozen salmon nasal cartilage prepared as described above in item (2), and allowing the mixture to stand, or heating the mixture at 100°C. More specifically, analysis was carried out as follows. Four samples were prepared. Each sample was prepared by adding 60 mL of distilled water to about 12 g of the small pieces of frozen salmon nasal cartilage. These four samples were heated at 100°C for 1 hour, 2 hours, 3 hours, and 4 hours, respectively, and each sample was centrifuged with a centrifugal separator at 5,000 rpm at 4°C for 20 minutes to remove insoluble matter (residue) and collect the supernatant. After the amount of the collected supernatant was measured, the amount of uronic acid in the supernatant was measured by the carbazole-sulfuric acid method. (The amount of uronic acid reflects the amount of proteoglycan. In the tables and figures, the amount of uronic acid may be represented using the term "GlcA," an abbreviation of glucuronic acid, which is a uronic acid.) In addition, the amount of protein in the collected supernatant was measured by the Bradford method. The results are shown in Table 1.
Fig. 2 is a graphical representation of Table 1. -
Table 1 Heating time (amount of small pieces (g)) Amount of liquid (mL) Per gram of small pieces of frozen salmon nasal cartilage GlcA/protein Residue amount (g) and state GlcA (mg) Protein (mg) 1 hour (12.261 g) 31.0 4.507 0.441 10.22 33.83 Slightly soft 2 hours (12.322 g) 40.0 8.069 0.883 9.14 28.49 Jelly-like state; shape easily collapses when pressed with a finger 3 hours (12.599 g) 45.5 8.636 1.039 8.31 21.79 About to lose its shape 4 hours (12.405 g) 61.5 15.592 3.401 4.58 5.56 No shape, mushy; small amount - From Table 1 and
Fig. 2 , it was found that the extraction amount of proteoglycan increases as the heating time is increased. It was also found that heating for more than 3 hours (e.g., 4 hours), in particular, increases the extraction amount of proteoglycan significantly. - Proteoglycan was also extracted from the frozen salmon nasal cartilage blocks from item (1) and from the defatted salmon nasal cartilage powder from item (3) in the same manner as for the small pieces of frozen salmon nasal cartilage from item (2) above (except that the heating time and the heating temperature were changed), and the extraction amounts thereof were compared. The results are shown in Table 2. In Table 2, the amount of extracted uronic acid and the amount of extracted protein are represented in terms of amounts per 100 g of the frozen salmon nasal cartilage blocks. The amount of protein was measured by the Bradford method.
Fig. 3 is a graphical representation of Table 2. The descriptions of the samples (1 to 9) shown inFig. 3 correspond to the descriptions of 1 to 9 of the Sample No. column in Table 2. -
Table 2 Extraction amounts per 100 g of the Frozen Salmon Nasal Cartilage Blocks (defatted salmon nasal cartilage powder: 5.83 g, small pieces of frozen salmon nasal cartilage: 95.6 g) Sample No. Heating temperature Heating time GlcA (mg) Protein (mg) GlcA/protein Defatted salmon nasal cartilage powder 1 4° C 2 hours 186.68 45.88 4.07 2 100° C 2 hours 581.43 136.25 4.27 3 100° C 4 hours 733.15 215.30 3.41 Frozen salmon nasal cartilage blocks 4 4° C 2 hours 96.90 - - 5 100° C 2 hours 499.90 96.90 5.16 6 100° C 4 hours 832.10 234.85 3.54 Small pieces of frozen salmon nasal cartilage 7 4° C 2 hours 150.67 18.55 8.12 8 100° C 2 hours 771.40 84.41 9.14 9 100° C 4 hours 1490.60 325.14 4.58 - When the frozen salmon nasal cartilage blocks were simply subjected to water extraction and were not heated, protein was not extracted. It was thus found that proteoglycan is not extracted under such extraction conditions.
- It was found that the amount of extracted uronic acid (which reflects the amount of proteoglycan) significantly increases, in particular, when the small pieces of frozen salmon nasal cartilage are heated in water at 100°C for 4 hours.
- To 20 g of the defatted salmon nasal cartilage powder described above, 1,000 mL of purified water at room temperature (pH of 6.5) was added, and the mixture was stirred for 30 minutes and then centrifuged (8,000 rpm, 30 minutes, 4°C) to collect the supernatant. The supernatant was freeze-dried to obtain a water extract of fish cartilage. The water extract of fish cartilage may be hereinafter referred to as Sample No. 10.
- Sample No. 10 was separated into fractions by gel filtration chromatography under the conditions described below. The amount of uronic acid contained in each fraction was quantified by the carbazole-sulfuric acid method. In addition, absorbency at 280 nm of each fraction was measured, and the absorbency was defined as a value reflecting the amount of protein contained therein. Based on these results, a uronic acid amount chromatogram and a 280-nm protein amount chromatogram were drawn.
Fig. 4a shows a superimposition of the uronic acid amount chromatogram and the 280-nm protein amount chromatogram.Fig. 4b shows the uronic acid amount chromatogram together with the position of each fraction at which each molecular weight marker was eluted. Since the amount of each fraction in the gel filtration chromatography was 1 mL/tube as described below, the horizontal axis, "Elution Volume (mL)", inFig. 4 also reflects the fraction No. - Column: Sepharose CL-2B packed column (1-cm dia. × 50 cm column packed with Sepharose CL-2B as a carrier. Sepharose CL-2B has a dextran fractionation range of 100 to 20,000 kDa and is available from GE Healthcare and other companies. Sepharose CL-2B, CAS registry No. 65099-79-8, is a 2% crosslinked agarose with a particle size of 60 to 200 µm (measured by the laser diffraction scattering method).)
Buffer: 0.1 M phosphate buffer (pH of 7.1, containing 0.2 M NaCl) Amount of applied sample: 4 mg of Sample No. 10 (dissolved in 1 mL of buffer for use)
Flow rate: 0.15 mL/min
Amount of fraction: 1 mL/tube
Molecular weight analytical curve: The various dextran molecular weight markers described below were subjected to gel filtration chromatography under the same conditions as described above (except that the amount of the sample was 1 mg/1 mL of buffer), and absorbency (which reflects the amount of dextran) of each fraction was measured by the phenol-sulfuric acid method, and an analytical curve was prepared. - Dextran from Leuconostoc mesenteroides (mol wt 5,000,000 - 40,000,000)(Sigma) ... For measuring the void volume of the column, 20,000 kDa
Dextran Standard 1,400,000 (Sigma) ... 1400 kDa
Dextran Standard 670,000 (Sigma) ... 670 kDa
Dextran Standard 410,000 (Sigma) ... 410 kDa
Dextran Standard 270,000 (Sigma) ... 270 kDa - The dextran from Leuconostoc mesenteroides was used after pretreatment was carried out to remove low molecular weight dextran contained in the marker. The pretreatment was performed by eluting dextran from Leuconostoc mesenteroides under the conditions described above in "Gel Filtration Chromatography Conditions" (the applied amount was the amount for marker) and collecting and freeze-drying fractions having a molecular weight of not less than 20,000 kDa. More specifically, fractions that corresponded to a peak that appeared first in a chromatogram reflecting the amount of dextran were collected and freeze-dried. The chromatogram was prepared by measuring the absorbency of each fraction by the phenol-sulfuric acid method. (It is believed that dextran having a molecular weight of not less than 20,000 kDa was obtained by collecting and freeze-drying such fractions.) This freeze-dried product was actually used as a marker (for measuring the void volume of the column).
Measurement of absorbency to obtain a chromatogram reflecting the amount of dextran was performed according to the method (the phenol-sulfuric acid method) described in Hodge, J. E. and Hofreiter, B. T., Method in Carbohydrate Chemistry, 1, 338 (1962). More specifically, the measurement was carried out as follows. - [1] 500 µL of a sample aqueous solution is placed in a 105 × 15 mm test tube.
- [2] 500 µL of a phenol reagent (5 v/v% aqueous phenol solution) is added thereto, and the mixture is stirred.
- [3] 2.5 mL of concentrated sulfuric acid is added thereto, and immediately the mixture is stirred vigorously for 10 seconds.
- [4] The mixture is left to stand for 20 minutes or more at room temperature.
- [5] The absorbency at 490 nm is measured with a spectrophotometer. The obtained analytical curve was (y = -4.1355Ln(x) + 59.47; R2 = 0.9869). From the R2 value, it was found that the molecular weight and the fraction No. (i.e., elution volume) were highly correlated.
- As shown in
Fig. 4b , Sample No. 10 was found to contain proteoglycan having a molecular weight of not less than 2,000,000 (200 × 104) (further, a molecular weight of not less than 2,500,000 (250 × 104)). As shown inFig. 4b , the ratio of the component having not less than (or not greater than) a specific molecular weight contained in the water extract of fish cartilage can be determined by drawing a vertical line from an elution volume point corresponding to the specific molecular weight in the uronic acid amount chromatogram and calculating the ratio of the two areas of the chromatogram divided by the vertical line. - Next, Sample No. 10 was analyzed in more detail. More specifically, the analysis was carried out as follows. Sample No. 10 was subjected to ion-exchange chromatography under the conditions described below to fractionate proteoglycan. More specifically, 16 mL eluted fractions were collected to quantify the amount of uronic acid by the carbazole-sulfuric acid method.
- Column: DEAE packed column (5.0-cm dia. × 20 cm column packed with DEAE (GE Healthcare) as a carrier)
Buffer: 7 M urea-Tris-hydrochloric acid buffer (pH of 7.2) Gradient:NaCl concentration 0 → 0.75 M
Amount of applied sample: 200 mg of Sample No. 10 (freeze-dried product of a water extract of fish cartilage) (dissolved in 50 mL of buffer and applied)
Flow rate: 2.0 mL/min
Amount of fraction: 16 mL/tube - The obtained uronic acid amount chromatogram was shown in
Fig. 5 . Fractions containing uronic acid (shown inFig. 6 as a left-right arrow) were collected, dialyzed, and then freeze-dried to obtain powder. The powder was used as a "proteoglycan fraction" for the following analysis. - The proteoglycan fraction obtained as described above was subjected to gel filtration chromatography under the following conditions and fractionated. The amount of uronic acid contained in each fraction was quantified by the carbazole-sulfuric acid method. In addition, absorbency at 280 nm of each fraction was measured and the absorbency was defined as a value reflecting the amount of protein contained therein. Based on these results, a uronic acid amount chromatogram and a 280-nm protein amount chromatogram were drawn.
- Column: Sepharose CL-2B packed column (5.0-cm dia. × 50 cm column packed with Sepharose CL-2B (GE Healthcare) as a carrier)
Buffer: 0.1 M phosphate buffer (pH of 7.1, containing 0.2 M NaCl) Amount of applied sample: 150 mg
Flow rate: 2.0 mL/min
Amount of fraction: 16 mL/tube - The various dextran molecular weight markers described below were also subjected to gel filtration chromatography under the same conditions (except that the amount of the sample was 50 mg), and absorbency of each eluted fraction (which reflects the amount of dextran) was measured by the phenol-sulfuric acid method. An analytical curve of molecular weights and fraction Nos. was obtained, and fraction Nos. having a molecular weight of 5,000,000 (500 × 104) and a molecular weight of 400,000 (40 × 104) were determined.
- Dextran from Leuconostoc mesenteroides (mol wt 5,000,000 - 40,000,000)(Sigma) ... 20,000 kDa
Dextran Standard 1,400,000 (Sigma) ... 1,400 kDa
Dextran Standard 270,000 (Sigma) ... 270 kDa - The dextran from Leuconostoc mesenteroides was used after pretreatment was carried out to remove low molecular weight dextran contained in the marker. The pretreatment was performed by eluting dextran from Leuconostoc mesenteroides under the conditions described above in "Gel Filtration Chromatography Conditions" (the applied amount was the amount in the marker treatment), and collecting and freeze-drying fractions having a molecular weight of not less than 20,000 kDa. More specifically, fractions that corresponded to a peak that first appeared in a chromatogram reflecting the amount of dextran were collected and freeze-dried. (It is believed that dextran having a molecular weight of not less than 20,000 kDa was obtained by collecting and freeze-drying such fractions.) This freeze-dried product was actually used as a marker (for measuring the void volume of the column). Measurement of absorbency to obtain a chromatogram reflecting the amount of dextran was performed in the same manner as described above.
- The obtained chromatograms were shown in
Fig. 6 . Fractions containing uronic acid were divided into three groups: a group having a molecular weight of not less than 5,000,000 (500 × 104), a group having a molecular weight of not less than 400,000 (40 × 104) to less than 5,000,000 (500 × 104), and a group having a molecular weight of less than 400,000 (40 × 104). The fractions were collected, dialyzed, and then freeze-dried to obtain three types of water extracts (powder) of fish cartilage having different molecular weights. These three types of water extracts of fish cartilage were used as PG-1 extract (containing proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104)), PG-2 extract (containing proteoglycan having a molecular weight of not less than 400,000 (40 × 104) to less than 5,000,000 (500 × 104)), and PG-3 extract (containing proteoglycan having a molecular weight of less than 400,000 (40 × 104)). From the results, it was confirmed that Sample No. 10 contained proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104). - A water extract of fish cartilage was actually given to mammals, and the effects of the extract were analyzed.
- Hairless mice (Hr-/Kud, male) (Kyudo Co., Ltd.) were used for the experiment. Male mice (6 weeks old), which are free of the influence of fluctuations in estrogen on skin conditions, were preliminarily fed, and then used for the experiment.
- The mice were placed in three feeding cages as shown in Table 3 to be divided into groups (
Groups 1 to 3)(six mice in one group). In addition, the subjects were marked on their tail portion to be individually identified. They continued to be preliminarily fed until the start of analysis. The average body weight during the experiment was 37 g. Sample No. 10 was used as the water extract of fish cartilage forGroup 3 in Table 3, which is an evaluation material. -
Table 3 Group Evaluation material UVB irradiation 1 Water (control) No 2 Water (control) Yes 3 Water extract of fish cartilage (0.175 mg/day/mouse) Yes - Sample No. 10 was dissolved in water to 0.35 mg/mL to prepare an administration sample.
- When the hairless mice reached 8 weeks of age, 0.5 mL of the administration sample was given once a day through forced oral administration using a sonde (0.175 mg/day/mouse). To the controls, 0.5 mL of distilled water was given. This administration was continued at a frequency of 6 times per week (once a day for 6 days, Monday to Saturday) until the end of the experiment.
- UVB irradiation started 3 weeks after oral administration began. The mice were placed in a cage for UVB irradiation. The cage was placed into a UVB irradiation device to carry out
UVB irradiation 6 times per week (once a day for 6 days, Monday to Saturday), at an intensity of 1.0 mW/cm2. The amount of irradiation was 60 mJ/cm2 during only the first week after the start of the irradiation, and 120 mJ/cm2 from the second week onward. Note that UVB was ultraviolet with a wavelength from 280 to 315 nm. - Erythema values after 4 weeks and 7 weeks of UVB irradiation were measured with a Mexameter, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate anti-inflammation. Five areas on the back of each mouse were measured, and the average value was calculated. Inflammation due to UVB irradiation causes erythema. Thus, a larger erythema value means severer inflammation.
Fig. 7 shows the results of measuring erythema values after 4 weeks and 7 weeks of UVB irradiation. From the results, it was found that erythema is reduced through oral administration of Sample No. 10, which is a water extract of fish cartilage. This indicates that the water extract of fish cartilage reduces inflammation caused by ultraviolet irradiation. - Transepidermal water loss (TEWL) after 4 weeks and 7 weeks of UVB irradiation was measured with a Tewameter, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate skin barrier functionality. Three areas on the back of each mouse were measured, and the average value was calculated. A larger TEWL value means lower skin barrier functionality (functions that prevent foreign matter outside the skin from penetrating into the body, and that prevent moisture inside the body from escaping to the outside).
Fig. 8 shows the results of measuring TEWL after 4 weeks and 7 weeks of UVB irradiation. The results reveal that oral administration of Sample No. 10, which is a water extract of fish cartilage, reduces the TEWL value and improves skin barrier functionality. - Skin anti-aging ability was analyzed using Sample No. 10, PG-1 extract, and PG-2 extract. PG-1 extract and PG-2 extract were obtained by further purifying Sample No. 10.
- Hairless mice (Hr-/Kud, male) (Kyudo Co., Ltd.) were used for the experiment. Male mice (6 weeks old), which are free of the influence of fluctuations in estrogen on skin conditions, were preliminarily fed, and then used for the experiment.
- The mice were placed in five feeding cages, as shown in Table 4, to be divided into groups (
Groups 1 to 5)(six mice in one group). In addition, the subjects were marked on their tail portion to be individually identified. They continued to be preliminarily fed until the start of analysis. -
Table 4 Group Evaluation material UVB irradiation 1 Water (control) No 2 Water (control) Yes 3 Sample No. 10 Yes 4 PG-1 extract Yes 5 PG-2 extract Yes - Evaluation materials were individually dissolved in water to 0.2 mg/mL to prepare administration samples.
- When the hairless mice reached 8 weeks of age, 0.5 mL of each administration sample was individually given once a day through forced oral administration using a sonde (0.1 mg/day). To the controls, 0.5 mL of distilled water was given. This administration was continued at a frequency of 6 times per week (once a day for 6 days, Monday to Saturday) until the end of the experiment.
- UVB irradiation started 3 weeks after the start of the oral administration. The mice were placed in a cage for UVB irradiation. The cage was placed into a UVB irradiation device to carry out
UVB irradiation 6 times per week (once a day for 6 days, Monday to Saturday), at an intensity of 1.0 mW/cm2. The amount of irradiation was 60 mJ/cm2 during only the first week after the start of the irradiation, and 120 mJ/cm2 from the second week onward. Note that UVB was ultraviolet with a wavelength from 280 to 315 nm. - Erythema values after 4 weeks and 7 weeks of UVB irradiation were measured with a Mexameter, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate anti-inflammation. Five areas on the back of each mouse were measured, and the average value was calculated. Inflammation due to UVB irradiation causes erythema. Thus, a larger erythema value means severer inflammation.
Fig. 9 shows the results of measuring erythema values after 4 weeks and 7 weeks of UVB irradiation. From the results, it was found that oral administration of the water extract of fish cartilage used reduces erythema, and thus reduces inflammation caused by ultraviolet irradiation. It was also found that in particular, high molecular weight proteoglycan (PG-1 extract) having a molecular weight of not less than 5,000,000 (500 × 104) exhibits a large effect among the proteoglycans contained in the water extract of fish cartilage. - Transepidermal water loss (TEWL) after 4 weeks and 7 weeks of UVB irradiation was measured with a Tewameter, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate skin barrier functionality. Three areas on the back of each mouse were measured, and the average value was calculated. A larger TEWL value means lower skin barrier functionality (functions that prevent foreign matter outside the skin from penetrating into the body, and that prevent moisture inside the body from escaping to the outside).
Fig. 10 shows the results of measuring TEWL after 4 weeks and 7 weeks of UVB irradiation. The results reveal that oral administration of the water extract of fish cartilage used reduces the TEWL value and improves skin barrier functionality. - Stratum corneum water content after 4 weeks and 7 weeks of UVB irradiation was measured with a Corneometer, a multiprobe skin measuring instrument (MPA580: Courage-Khazaka), to evaluate skin water retention ability. Ten areas on the back of each mouse were measured, and the average value was calculated.
Fig. 11 shows the results of measuring TEWL after 4 weeks and 7 weeks of UVB irradiation. From the results, it was found that oral administration of the water extract of fish cartilage used increases stratum corneum water content and improves skin water retention ability. It was also found that, in particular, proteoglycan (PG-1 extract) having a molecular weight of not less than 5,000,000 (500 × 104) exhibits a large effect among the proteoglycans contained in the water extract of fish cartilage. - The symbols in
Figs. 7 to 11 mean the following.
*** : p < 0.001
** : p < 0.01
* : p < 0.05
+ : p < 0.1 - The skin of the inner forearm and the upper inner arm of each subject (14 healthy females aged 25-55) was irritated with a chamber impregnated with sodium dodecyl sulfate (SLS) by the method described below, and changes after the irritation in the erythema disappearance rate (measured at the forearm) and in transepidermal water loss (TEWL) (measured at the upper arm) were compared. (The details of the test method are described below.)
- Sample No. 10 (500 mg) used for the test group was inserted into six hard capsules, and crystalline cellulose powder (Ceolus (registered trademark) FD-301 (produced by Asahi Kasei Chemicals Corp.)) (500 mg) used as a placebo was inserted into six hard capsules. Each of them was orally administered to their respective subjects twice a day at a rate of three capsules each time (i.e., the daily intake was 500 mg). Sample No. 10 was orally administered to seven subjects, and the placebo was orally administered to seven subjects.
- Sample No. 10 (500 mg) contained about 80 mg of proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104). This value (about 80 mg) was determined as follows. Fractions (Nos. 16 to 23) that correspond to proteoglycan having a molecular weight of not less than 5,000,000 (500 × 104) in the uronic acid amount chromatogram of Sample No. 10 in
Fig. 4 were collected, dialyzed, and freeze-dried to measure the dry weight thereof. The ratio of the dry weight to the amount (4 mg) of Sample No. 10 applied in the column for preparing the chromatogram inFig. 4 was determined, and 500 mg was multiplied by this ratio to obtain the above value. - In the fifth week after the start of the administration (the administration continuing until the end of the measurement), a chamber impregnated with SLS was applied to the skin of the inner forearm and the upper inner arm of each subject to irritate the skin. Thereafter, the color of erythema on the forearm after the irritation (value a* in the L*a*b* color system) and the transepidermal water loss (TEWL) value of the upper arm after the irritation were measured at the irritated site and the non-irritated site of the arm. The relative value (control ratio) of the measured value of the irritated site to the measured value of the non-irritated site was calculated to examine changes in the erythema disappearance rate and in TEWL. The results are shown in
Figs. 12 and13 . - More specifically, the skin irritation and the measurement were performed as follows.
- After washing the inner arm, each subject was in a constant temperature, constant humidity room at 22°C with a relative humidity of 60% for 15 minutes or more. Subsequently, a chamber (200 large Finn Chambers on Scanpor, Norgeplaster Ltd.) with filter paper impregnated with 30 µL of 0.5% SLS (sodium dodecyl sulfate: Wako Pure Chemical Industries, Ltd., Lot. STQ8638) was applied to the skin on the inner arm of each subject to expose the skin to irritation under occlusion for 4 hours. Thereafter, the chamber was removed, and 1 hour, 1 day, and 2 days after the removal, the color of erythema at the irritated site (value a*) was measured with a CR-400 Chroma Meter (Konica Minolta), and the TEWL value at the irritated site was measured with a Tewameter TM-300 (Courage-Khazaka).
- From
Fig. 12 , it was confirmed that oral administration of Sample No. 10 increases the rate at which erythema disappears (i.e., alleviates inflammation). FromFig. 13 , it was also confirmed that oral administration of Sample No. 10 decreases the TEWL value (i.e., improves and enhances skin barrier functionality). - To 500 g of the small pieces of defatted salmon nasal cartilage described above, purified water was added in an amount that is 2.5 times the mass of the small pieces, and each mixture was heated at 100°C, 90°C, 70°C, or 50°C. The heating times at 100°C and 90°C were 3 hours each, and the heating times at 70°C and 50°C were 6 hours each. The cartilage was completely dissolved in the heating at 100°C and in the heating at 90°C, whereas the cartilage was not completely dissolved in the heating at 70°C or in the heating at 50°C, and thus the extraction ended with partially remaining cartilage. Centrifugation was performed for each mixture with a centrifugal separator at 8,000 rpm at 4°C for 30 minutes to remove insoluble matter (residue) and collect the supernatant, and the supernatant was freeze-dried to prepare freeze-dried samples (FD samples). These samples may be hereinafter referred to as a 100°C extraction FD sample, 90°C extraction FD sample, 70°C extraction FD sample, and 50°C extraction FD sample. In addition, a freeze-dried sample was obtained by heating a mixture of the small pieces of defatted salmon nasal cartilage and purified water at 100°C for 3 hours and then further for 3 hours and performing centrifugation and freeze drying in the same manner. This sample may be hereinafter referred to as a 100°C (3h) extraction FD sample.
- Each of these FD samples was adjusted such that the GlcA concentration was 1 mg/1 mL of buffer and analyzed for the molecular weight of each sample by gel filtration chromatography in the same manner as the chromatography that was used to first analyze Sample No. 10 in the "Analysis of Molecular Weight of Proteoglycan" (the results of this chromatography being shown in
Fig. 4 ) described above. More specifically, the percentage of the component having a molecular weight of not less than 5,000,000 (500 × 104), the percentage of the component having a molecular weight of not less than 2,500,000 (250 × 104), and the percentage of the component having a molecular weight of not less than 1,800,000 (180 × 104) were determined from each uronic acid amount chromatogram. The results are shown in Table 5. -
Table 5 ≥ 5,000,000 (500 × 104) Da ≥ 2,500,000 (250 × 104) Da ≥ 1,800,000 (180 × 104) Da 50°C extraction FD 34.0% 50.6% 60.9% 70°C extraction FD 37.5% 52.7% 61.9% 90°C extraction FD 39.7% 54.0% 62.3% 100°C extraction FD 39.1% 52.8% 61.2% 100°C (3 h) extraction FD 26.2% 41.1% 51.1% - Subsequently, the samples were analyzed for cell proliferation ability as follows. Specifically, in a culturing dish for each sample, human skin fibroblasts (HDF53: Cell Applications, Inc.) were seeded at 1.5 × 104 cells in minimum essential medium (MEM) containing 10% fetal bovine serum (FBS). Each sample was filter-sterilized with a 22-µm filter and added individually to MEM to a concentration of 20 µg/mL. After the addition, the cells were cultured for five days. Following the culture, the MEM was removed, and the cells were detached and suspended with Trypsin-EDTA (Invitrogen). Thereafter, Trypan blue stain was added, and the number of cells was counted using a counting chamber.
- Water was used as the control. Further, a product commercially available as proteoglycan (referred to as commercially available product A) was also analyzed in the same manner for comparison.
- The results are shown in
Fig. 14 . The 90°C extraction FD sample significantly promoted cell proliferation compared to the control. The 70°C extraction FD sample and the 100°C extraction FD sample also showed a tendency to promote cell proliferation. In the analysis, the number of samples (n) was 11 for the control, 3 for the 50°C extraction FD sample, 6 for the 70°C extraction FD sample, 11 for the 90°C extraction FD sample, 6 for the 100°C extraction FD sample, 6 for the 100°C (3 h) extraction FD sample, and 5 for commercially available product A. Student's t-test was used for statistical processing. - Further, the composition of each sample used for the analysis was analyzed. Analysis of each component was performed as follows. For measurement of amounts of protein, lipid, ash, moisture, and hydroxyproline (used for measuring the amount of collagen), the samples were submitted to Japan Food Research Laboratories to have analysis conducted on components per 100 g of each sample. The amount of protein was measured by the Kjeldahl method, the amount of lipid was measured by the acid hydrolysis method, the amount of ash was measured by the direct ashing method, the amount of moisture was measured by the normal-pressure heat-drying method, and the amount of hydroxyproline was measured by automatic amino acid analysis (HPLC method). The amount of carbohydrate was calculated by subtracting the amounts of protein, lipid, ash, and moisture from 100 (g).
- As described above, the amount of protein was measured by the Kjeldahl method, which uses the amount of nitrogen as an indicator. Since nitrogen derived from glycosaminoglycan is also measured, adjustment was carried out as follows.
- To subtract nitrogen derived from glycosaminoglycan, which is not protein, the amount of the acidic saccharide component (in terms of chondroitin sulfate) was calculated from the amount of uronic acid determined by the carbazole-sulfuric acid method. (Specifically, the amount of uronic acid was multiplied by a conversion factor of 2.593). Since nitrogen derived from chondroitin sulfate corresponds to 2.9% of molecular weight, the obtained amount of the acidic saccharide component was multiplied by 2.9% to calculate nitrogen derived from glycosaminoglycan.
- The nitrogen obtained by subtracting nitrogen derived from glycosaminoglycan includes nitrogen derived from collagen and nitrogen derived from protein other than collagen. Since the "protein factor" of collagen is different from that of the other protein, it is necessary to ascertain the amount of nitrogen derived from collagen and the amount of nitrogen derived from the other protein.
- Collagen was quantified by quantifying "hydroxyproline," which is an amino acid specifically present in collagen, as described above. More specifically, collagen content was determined by measuring hydroxyproline (Hyp), which is an amino acid specifically present in collagen, and assuming that collagen contains 6.7% Hyp. The thus-obtained amount of collagen was divided by 5.55, which is the protein factor of collagen, to calculate the amount of nitrogen derived from collagen.
- The amount of nitrogen derived from glycosaminoglycan and the amount of nitrogen derived from collagen were subtracted from the quantified value of nitrogen determined by the Kjeldahl method, and the value obtained by the subtraction was multiplied by 6.25, which is the protein factor of general protein, to calculate the amount of protein other than collagen.
- The amount of protein was calculated by adding the amount of collagen to the amount of protein other than collagen determined as described above.
- The results are shown in the following Table 6. The values in Table 6 represent grams per 100 g of extraction FD sample. Table 6 also shows the amount of proteoglycan having a molecular weight of not less than 1,800,000 (180 × 104). The amount of proteoglycan having a molecular weight of not less than 1,800,000 (180 × 104) was obtained by multiplying the amount of glycosaminoglycan listed in Table 6 by the percentage of the component having a molecular weight of not less than 1,800,000 (180 × 104) listed in Table 5.
-
Table 6 (1) 100°C extraction FD (2) 90°C extraction FD (2) 70°C extraction FD (3) 50°C extraction FD (4) 10% EtOH treatment → 90°C extraction FD Commercially available product A (20% standard product) Moisture 8.1 7.8 10.4 3.7 7.8 7.4 Protein 54.6 52.9 35.2 36.5 56.9 7.1 Collagen in protein 50.9 49.9 31.3 33.4 53.1 2.54 Lipid 3.4 0.7 2.1 5 1.2 0.2 Ash 8.2 7.7 9.7 12 7.2 5.3 Carbohydrate 24.3 21.5 30.9 32.6 21.8 77.7 Total 100 100 100 100 100 100 Glycosaminoglycan 42.0 33.9 40.7 35.0 42.5 20 (standard value) Proteoglycan having a molecular weight of not less than 1,800,000 (180 × 104) 25.7 21.1 25.2 21.3 27.4 ND Unit: grams per 100 g of extraction FD sample
Acidic saccharide: calculated as chondroitin sulfate equivalent amount Chondroitin sulfate equivalent amount = the amount of glucuronic acid × conversion factor of 2.593 - Further, the expression "10% EtOH treatment → 90°C extraction FD" in Table 6 refers to a sample obtained by defatting fish cartilage with 10% ethanol and then performing extraction with water at 90°C. More specifically, to 500 g of the small pieces of frozen salmon nasal cartilage, a 10% EtOH solution was added in an amount 2.5 times that of the small pieces, and the mixture was stirred with a stirrer at room temperature for 24 hours and centrifuged at 8,000 rpm at 4°C for 30 minutes. The collected insoluble matter (residue containing cartilage) was heated until the cartilage was completely dissolved through extraction at 90°C with propeller stirring, and then centrifugation and filtration were performed in the same manner as in the FD samples shown in Table 5 to obtain the freeze-dried (FD) sample.
- As shown in Table 6, most of the protein contained in the water extract of fish cartilage according to the present invention is collagen. Further, in particular, it can be seen that the smaller the lipid content or ash content is, the more the water extract of fish cartilage has cell proliferation ability (i.e., exhibits the cell proliferation promoting effect). It is believed that the water extract of fish cartilage having cell proliferation ability more efficiently provides the inflammation alleviation effect or anti-aging effect.
Claims (8)
- A water extract of fish cartilage comprising a proteoglycan having a molecular weight of not less than 1,800,000 (180×104).
- The water extract of fish cartilage according to claim 1, comprising a proteoglycan having a molecular weight of not less than 2,500,000 (250×104).
- The water extract of fish cartilage according to claim 2, comprising a proteoglycan having a molecular weight of not less than 5,000,000 (500×104).
- The water extract of fish cartilage according to claim 3, comprising, on a dry mass basis, 9 mass% or more of a proteoglycan having a molecular weight of not less than 5,000,000 (500×104).
- The water extract of fish cartilage according to any one of claims 1 to 4, comprising, on a dry mass basis, 30 mass% or more of collagen.
- The water extract of fish cartilage according to any one of claims 1 to 5, wherein the fish is salmon or trout, and the cartilage is nasal cartilage.
- A food/drink composition, an oral composition, or a cosmetic composition comprising the water extract of fish cartilage according to any one of claims 1 to 6.
- The composition according to claim 7, for use in alleviation of inflammation or anti-aging.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011009284 | 2011-01-19 | ||
PCT/JP2012/051131 WO2012099224A1 (en) | 2011-01-19 | 2012-01-19 | Extract of aquatic animal cartilage |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2666467A1 true EP2666467A1 (en) | 2013-11-27 |
EP2666467A4 EP2666467A4 (en) | 2014-11-19 |
Family
ID=46515843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12737027.8A Withdrawn EP2666467A4 (en) | 2011-01-19 | 2012-01-19 | Extract of aquatic animal cartilage |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130310540A1 (en) |
EP (1) | EP2666467A4 (en) |
JP (5) | JP6362825B2 (en) |
CN (1) | CN103327987A (en) |
WO (1) | WO2012099224A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226422B2 (en) | 2013-01-23 | 2019-03-12 | Bottled Science Limited | Skin enhancing beverage composition |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2455097B1 (en) | 2009-07-16 | 2016-02-17 | Sunstar Inc. | Proteoglycan-containing material |
CN103327987A (en) * | 2011-01-19 | 2013-09-25 | 国立大学法人弘前大学 | Extract of aquatic animal cartilage |
CN103429608B (en) | 2011-01-19 | 2016-08-03 | 国立大学法人弘前大学 | A large amount of preparation methoies of proteoglycan |
WO2014017570A1 (en) * | 2012-07-25 | 2014-01-30 | 国立大学法人弘前大学 | Composition for preventing or treating osteoarthrosis |
WO2015005829A1 (en) * | 2013-07-10 | 2015-01-15 | Samarchev Yannis Sergeevich | Beverage made of jellyfish and production method thereof |
JP6005780B2 (en) * | 2015-03-02 | 2016-10-12 | 株式会社Agt&T | Nail art removing method and forming method, and fingertip protecting agent |
JP6925663B2 (en) * | 2015-09-03 | 2021-08-25 | 地方独立行政法人青森県産業技術センター | Anti-glycation agent |
JP2017125164A (en) * | 2016-01-15 | 2017-07-20 | 地方独立行政法人青森県産業技術センター | High water holding modified proteoglycan |
US10253090B2 (en) | 2016-03-22 | 2019-04-09 | Avicenna Nutraceutical, Llc | Hydrolyzed collagen compositions and methods of making thereof |
JP2018090552A (en) * | 2016-12-07 | 2018-06-14 | 株式会社ウェルヴィーナス | Arthralgia improver |
JP7182917B2 (en) * | 2017-06-30 | 2022-12-05 | サンスター株式会社 | Composition for skin improvement |
JP7193069B2 (en) * | 2018-01-31 | 2022-12-20 | 国立大学法人弘前大学 | Iron salt of proteoglycan, proteoglycan, method for producing the same, cell growth promoter, and preparation for external use |
CN111670106B (en) | 2018-02-02 | 2022-04-15 | 三菱化学株式会社 | Material for three-dimensional molding, filament for three-dimensional molding, wound body of the filament, and three-dimensional printer cartridge |
WO2024097704A1 (en) * | 2022-11-02 | 2024-05-10 | Zanda, Llc | Herbal formulation for improvement of skin growth |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1614697A1 (en) * | 2003-03-20 | 2006-01-11 | Hosokawa Micron Corporation | Proteoglycan isolated from cartilaginous fish and process for producing the same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4350682A (en) * | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
CN1288165C (en) * | 1997-07-11 | 2006-12-06 | Cv技术公司 | A preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium |
JP2001172296A (en) * | 1999-10-07 | 2001-06-26 | Japan Science & Technology Corp | Method for purifying cartilage type proteoglycan |
JP2003299497A (en) * | 2002-02-05 | 2003-10-21 | Masayoshi Kachi | Mucopolysaccharide and method for producing the same |
WO2007094248A1 (en) * | 2006-02-14 | 2007-08-23 | Kushiro Industrial Technology Center | Process for producing proteoglycan |
JP4035553B2 (en) * | 2006-03-20 | 2008-01-23 | 株式会社日本バリアフリー | Method for producing useful composition |
JP5252623B2 (en) * | 2008-01-22 | 2013-07-31 | 国立大学法人弘前大学 | Extraction method of proteoglycan |
EP2455097B1 (en) * | 2009-07-16 | 2016-02-17 | Sunstar Inc. | Proteoglycan-containing material |
CN103327987A (en) * | 2011-01-19 | 2013-09-25 | 国立大学法人弘前大学 | Extract of aquatic animal cartilage |
-
2012
- 2012-01-19 CN CN2012800059678A patent/CN103327987A/en active Pending
- 2012-01-19 EP EP12737027.8A patent/EP2666467A4/en not_active Withdrawn
- 2012-01-19 US US13/980,429 patent/US20130310540A1/en not_active Abandoned
- 2012-01-19 JP JP2012553774A patent/JP6362825B2/en active Active
- 2012-01-19 WO PCT/JP2012/051131 patent/WO2012099224A1/en active Application Filing
-
2016
- 2016-08-23 JP JP2016163011A patent/JP6678895B2/en active Active
-
2018
- 2018-01-15 JP JP2018004122A patent/JP6510087B2/en active Active
- 2018-10-09 JP JP2018191096A patent/JP6896689B2/en active Active
-
2020
- 2020-11-04 JP JP2020184706A patent/JP7141645B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1614697A1 (en) * | 2003-03-20 | 2006-01-11 | Hosokawa Micron Corporation | Proteoglycan isolated from cartilaginous fish and process for producing the same |
Non-Patent Citations (4)
Title |
---|
GOTO M ET AL: "Anti-aging effects of high molecular weight proteoglycan from salmon nasal cartilage in hairless mice", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 2012 SPANDIDOS PUBLICATIONS LTD. GRC, vol. 29, no. 5, May 2012 (2012-05), pages 761-768, XP055144959, ISSN: 1107-3756 * |
ROTH ANDREAS ET AL: "Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 3, 31 March 2005 (2005-03-31), pages R677-R686, XP021011608, ISSN: 1465-9905, DOI: 10.1186/AR1725 * |
See also references of WO2012099224A1 * |
YOHTARO KATAGATA: "Anti-aging effects of extracts prepared from salmon nasal cartilage in hairless mice", MOLECULAR MEDICINE REPORTS, 23 May 2011 (2011-05-23), XP055145972, ISSN: 1791-2997, DOI: 10.3892/mmr.2011.498 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226422B2 (en) | 2013-01-23 | 2019-03-12 | Bottled Science Limited | Skin enhancing beverage composition |
Also Published As
Publication number | Publication date |
---|---|
JPWO2012099224A1 (en) | 2014-06-30 |
JP2017014265A (en) | 2017-01-19 |
JP6896689B2 (en) | 2021-06-30 |
JP6362825B2 (en) | 2018-07-25 |
JP7141645B2 (en) | 2022-09-26 |
EP2666467A4 (en) | 2014-11-19 |
JP2019031523A (en) | 2019-02-28 |
JP6678895B2 (en) | 2020-04-15 |
JP6510087B2 (en) | 2019-05-08 |
WO2012099224A1 (en) | 2012-07-26 |
JP2018108999A (en) | 2018-07-12 |
JP2021014463A (en) | 2021-02-12 |
US20130310540A1 (en) | 2013-11-21 |
CN103327987A (en) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2666467A1 (en) | Extract of aquatic animal cartilage | |
US9585828B2 (en) | Proteoglycan-containing material | |
TWI381834B (en) | Abnormal protein removal composition | |
EP2666779B1 (en) | Method for mass preparation of proteoglycan | |
JP5011121B2 (en) | Composition for promoting collagen and / or hyaluronic acid production | |
JP7213307B2 (en) | Composition for activating protein L-isoaspartate methyltransferase | |
KR20170093694A (en) | Collagen hydrolysate having high concentration of collagen tripeptide and uses thereof | |
WO2021005941A1 (en) | Albizia julibrissin extract-containing composition | |
Goto et al. | Anti-aging effects of extracts prepared from salmon nasal cartilage in hairless mice | |
JP2024521213A (en) | Shihe car imitation cosmetic composition | |
JP6723979B2 (en) | Wrinkle improver | |
KR20210152411A (en) | Food Composition Comprising the Extract of Chaenomelis langenariae radix for Improving Skin | |
KR20110115803A (en) | Compositions for external application to the skin having a promotion activity of collagen synthesis | |
KR20210066537A (en) | A composition for improving skin beauty containing glycosaminoglycan extracted from insect | |
KR20110087750A (en) | Compositions for promotion of collagen synthesis | |
JP2023165834A (en) | Damage recovery agent and hair cosmetic | |
JP2020073585A (en) | Wrinkle improver | |
KR20170114741A (en) | Composition for improving skin conditions | |
KR20170114736A (en) | Composition for improving skin conditions | |
JP2009084210A (en) | Cell activator | |
NZ614126B2 (en) | Method for mass preparation of proteoglycan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130731 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KATO, YOJI Inventor name: TAKAI, MOTOKO Inventor name: KATAGATA, YOHTARO Inventor name: GOTO, MASASHI Inventor name: SUEKAWA, YUTAKA Inventor name: YAMAMOTO, KAZUSHI Inventor name: HANADA, YUKAKO Inventor name: MAEDA, MARIKO |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20141020 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/78 20060101ALN20141014BHEP Ipc: A61K 38/00 20060101ALI20141014BHEP Ipc: A23L 2/66 20060101ALN20141014BHEP Ipc: A61K 38/17 20060101ALI20141014BHEP Ipc: C08B 37/00 20060101ALI20141014BHEP Ipc: A61K 35/60 20060101AFI20141014BHEP Ipc: A61K 8/64 20060101ALI20141014BHEP Ipc: A61K 8/98 20060101ALI20141014BHEP Ipc: A61K 38/01 20060101ALN20141014BHEP Ipc: C07K 14/46 20060101ALI20141014BHEP Ipc: A23L 1/305 20060101ALN20141014BHEP Ipc: A61P 29/00 20060101ALI20141014BHEP Ipc: A23L 1/30 20060101ALI20141014BHEP Ipc: A61P 17/16 20060101ALI20141014BHEP Ipc: A61Q 19/08 20060101ALI20141014BHEP |
|
17Q | First examination report despatched |
Effective date: 20160519 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160930 |